Pressure BioSciences (PBIO) 10-K 5 Apr 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Apr. 01, 2016	Jun. 30, 2015
Document And Entity Information
Entity Registrant Name	PRESSURE BIOSCIENCES INC
Entity Central Index Key	830,656
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		23,209,898
Entity Public Float			$ 4,249,932
Trading Symbol	PBIO
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 116,783	$ 473,948
Accounts receivable	113,256	272,022
Inventories, net of $50,000 reserve at December 31, 2015 and December 31, 2014	1,038,371	850,552
Prepaid income taxes	7,381	7,381
Prepaid expenses and other current assets	213,926	104,204
Total current assets	1,489,717	$ 1,708,107
Investment in available-for-sale equity securities	294,522
Property and equipment, net	20,149	$ 36,025
TOTAL ASSETS	1,804,388	1,744,132
CURRENT LIABILITIES
Accounts payable	941,389	1,035,781
Accrued employee compensation	176,009	157,347
Accrued professional fees and other	821,088	719,432
Deferred revenue	140,878	27,117
Convertible debt, net of unamortized discounts of $0 and $328,681, respectively	100,000	1,004,513
Other debt, net of unamortized discounts of $3,041 and $0, respectively	151,628	80,480
Warrant derivative liabilies	3,295,976	159,875
Conversion option derivatives liabilities	3,940,791	590,341
Total current liabilities	9,567,759	$ 3,774,886
LONG TERM LIABILITIES
Convertible debt, net of unamortized discounts of $5,223,658 and $0, respectively	177,342
Deferred revenue	36,935	$ 28,977
TOTAL LIABILITIES	9,782,036	3,803,863
STOCKHOLDERS' DEFICIT
Common stock, $.01 par value; 100,000,000 shares authorized; 23,004,898 and 18,673,390 shares issued and outstanding on December 31, 2015 and 2014, respectively	230,050	186,734
Warrants to acquire common stock	5,416,681	5,253,566
Additional paid-in capital	26,036,733	$ 24,617,564
Accumulated other comprehensive income	(105,025)
Accumulated deficit	(39,557,206)	$ (32,118,714)
Total stockholders' deficit	(7,977,648)	(2,059,731)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,804,388	1,744,132
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	3	3
Series G Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	866	866
Series H Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	$ 100	$ 100
Series H2 Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value
Series J Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	$ 36	$ 36
Series K Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	$ 114	$ 114

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventories reserve	$ 50,000	$ 50,000
Convertible debt, current unamortized discounts	0	328,681
Other debt, unamortized discounts	3,041	$ 0
Convertible debt, non current unamortized discounts	$ 5,223,658
Convertible preferred stock, par value	$ 0.01
Convertible preferred stock, authorized	1,000,000
Convertible preferred stock, shares issued	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	23,004,898	18,673,390
Common stock, shares outstanding	23,004,898	18,673,390
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	850	850
Convertible preferred stock, shares issued	300	300
Convertible preferred stock, shares outstanding	300	300
Convertible preferred stock, liquidation value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	240,000	240,000
Convertible preferred stock, shares issued	86,570	86,570
Convertible preferred stock, shares outstanding	86,570	86,570
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	10,000	10,000
Convertible preferred stock, shares issued	10,000	10,000
Convertible preferred stock, shares outstanding	10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	21	21
Convertible preferred stock, shares issued	21	21
Convertible preferred stock, shares outstanding	21	21
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	6,250	6,250
Convertible preferred stock, shares issued	3,546	3,546
Convertible preferred stock, shares outstanding	3,546	3,546
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	15,000	15,000
Convertible preferred stock, shares issued	11,416	11,416
Convertible preferred stock, shares outstanding	11,416	11,416

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue:
Products, services, other	$ 1,409,991	$ 1,350,150
Grant revenue	387,700	24,594
Total revenue	1,797,691	1,374,744
Costs and expenses:
Cost of products and services	609,054	652,438
Research and development	1,105,295	952,555
Selling and marketing	745,574	721,229
General and administrative	2,902,950	2,386,872
Total operating costs and expenses	5,362,873	4,713,094
Operating loss	(3,565,182)	(3,338,350)
Other (expense) income:
Interest expense	(4,146,416)	(1,303,129)
Other expense	(36,879)	$ (169,554)
Gain on extinguishment of embedded derivative liabilities	2,555,180
Change in fair value of derivative liabilities	(2,222,001)	$ 198,493
Total other (expense) income	(3,850,116)	(1,274,190)
Net loss	(7,415,298)	(4,612,540)
Accrued dividends on convertible preferred stock	$ (23,194)	(141,317)
Deemed dividends on convertible preferred stock		(1,497,869)
Net loss applicable to common shareholders	$ (7,438,492)	$ (6,251,726)
Net loss per share attributable to common stockholders - basic and diluted	$ (0.36)	$ (0.44)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	20,726,205	14,264,753

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Comprehensive Loss
Net loss	$ (7,415,298)	$ (4,612,540)
Other comprehensive loss
Unrealized loss on marketable securities	(105,025)
Comprehensive loss	$ (7,520,323)	$ (4,612,540)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Series D Preferred Stock [Member]	Series G Preferred Stock [Member]	Series H Preferred Stock [Member]	Series H2 Preferred Stock [Member]	Series J Preferred Stock [Member]	Series K Preferred Stock [Member]	Common Stock [Member]	Stock Warrants [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2013	$ 3	$ 1,453	$ 100		$ 51	$ 40	$ 120,243	$ 4,267,402	$ 19,509,921		$ (25,866,988)	$ (1,967,775)
Balance, shares at Dec. 31, 2013	300	145,320	10,000		5,088	4,000	12,024,267
Stock-based compensation									101,125			$ 101,125
Conversion of Series G convertible preferred stock		$ (587)					$ 5,875		(5,288)
Conversion of Series G convertible preferred stock, shares		(58,750)					587,500
Conversion of Series J convertible preferred stock					$ (15)		$ 15,410		(15,395)
Conversion of Series J convertible preferred stock, shares					(1,542)		1,541,000
Conversion of Series K convertible preferred stock						$ (11)	$ 10,990		(10,980)
Conversion of Series K convertible preferred stock, shares						(1,099)	1,099,000
Issuance of Series K convertible preferred stock						$ 82		$ 654,845	1,592,432			$ 2,247,359
Issuance of Series K convertible preferred stock, shares						8,176
Issuance of common stock for services							$ 5,888		208,304			214,192
Issuance of common stock for services, shares							588,830
Exercise of warrants							$ 5,967		143,198			149,165
Exercise of warrants, shares							596,658
Warrant exercise - reset / revaluation							$ 36,120	$ 163,654	662,745			862,519
Warrant exercise - reset / revaluation, shares							3,612,000
Offering costs for issuance of preferred stock									$ (8,000)			(8,000)
Issuance of warrants								$ 49,599				49,599
Issuance of warrants, shares
Issuance of warrants for services								93,488				93,488
Issuance of stock in lieu of cash for Board of Director fees						$ 3		$ 24,578	$ 60,169			$ 84,750
Issuance of stock in lieu of cash for Board of Director fees, shares						339
Deemed dividend associated with beneficial conversion of preferred stock									1,495,415		$ (1,495,415)
Conversion of debt and interest for commons stock							$ 5,100		$ 131,400			$ 136,500
Conversion of debt and interest for commons stock, shares							510,000
Conversion of preferred stock to common stock
Conversion of preferred stock to common stock, shares
Conversion of common stock to Series H2 preferred stock							$ (21,000)		$ 21,000
Conversion of common stock to Series H2 preferred stock, shares				21			(2,100,000)
Dividends earned											$ (143,771)	$ (143,771)
Warrants issued with debt
Write off of Series D warrant liability									$ 330,405			$ 330,405
Write off of conversion option									320,338			320,338
Issuance of common stock for dividends paid in kind							$ 2,141		$ 80,774			82,916
Issuance of common stock for dividends paid in kind, shares							214,135
Net loss											$ (4,612,540)	(4,612,540)
Balance at Dec. 31, 2014	$ 3	$ 866	$ 100		$ 36	$ 114	$ 186,734	$ 5,253,566	$ 24,617,564		$ (32,118,714)	(2,059,731)
Balance, shares at Dec. 31, 2014	300	86,570	10,000	21	3,546	11,416	18,673,390
Stock-based compensation									208,989			208,989
Issuance of common stock for services							$ 17,551		$ 439,479			$ 457,030
Issuance of common stock for services, shares							1,755,091					1,755,091
Warrant exercise - reset / revaluation								$ 69,627				$ 69,627
Warrant exercise - reset / revaluation, shares
Issuance of warrants							$ 10,000		$ 389,547			399,547
Issuance of warrants, shares							1,000,000
Issuance of warrants for services								$ 93,488				93,488
Conversion of debt and interest for commons stock							$ 15,765		$ 381,154			396,919
Conversion of debt and interest for commons stock, shares							1,576,417
Dividends earned											$ (23,194)	(23,194)
Unrealized loss on investments, net of tax										$ (105,025)		(105,025)
Net loss											$ (7,415,298)	(7,415,298)
Balance at Dec. 31, 2015	$ 3	$ 866	$ 100		$ 36	$ 114	$ 230,050	$ 5,416,681	$ 26,036,733	$ (105,025)	$ (39,557,206)	$ (7,977,648)
Balance, shares at Dec. 31, 2015	300	86,570	10,000	21	3,546	11,416	23,004,898

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,415,298)	$ (4,612,540)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	25,288	65,714
Accretion of interest and amortization of debt discount	2,989,765	1,310,351
Stock-based compensation expense	208,989	$ 101,125
Warrant expense	163,115
Amortization of third party fees paid in common stock	$ 457,030	$ 307,013
Amortization of board of director fees paid in preferred stock		$ 84,750
Gain on extinguishment of embedded derivative liabilities	$ (2,555,180)
Change in fair value of derivative liabilities	2,222,001	$ (198,493)
Changes in operating assets and liabilities:
Accounts receivable	158,766	(124,387)
Inventories	(187,820)	(113,876)
Prepaid expenses and other assets	(15,722)	(18,631)
Accounts payable	(94,392)	(66,991)
Accrued employee compensation	18,662	8,014
Deferred revenue and other accrued expenses	205,050	47,373
Net cash used in operating activities	(3,819,746)	(3,210,578)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment	(9,412)	(7,139)
Net cash used in investing activities	(9,412)	$ (7,139)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from related party debt	6,300
Payment of related party debt	(12,300)	$ (6,394)
Net proceeds from convertible debt	5,558,537	1,126,744
Payments on convertible debt	(2,653,990)	(303,100)
Net proceeds from non-convertible debt	1,257,418	302,252
Payments on non-convertible debt	(587,949)	$ (410,297)
Payment of accrued prepayment penalty	$ (96,023)
Net proceeds from the exercise of common stock warrants		$ 149,165
Net proceeds from warrant reset transaction		862,518
Net proceeds from the issuance of convertible preferred stock		1,939,360
Net cash provided by financing activities	$ 3,471,993	3,660,248
NET DECREASE IN CASH	(357,165)	442,531
CASH AT BEGINNING OF YEAR	473,948	31,417
CASH AT END OF PERIOD	116,783	473,948
SUPPLEMENTAL INFORMATION
Interest paid in cash	$ 1,072,900	$ 14,832
Income taxes paid in cash
NON CASH TRANSACTIONS:
Shares issued for conversion of debt and interest	$ 396,919	$ 136,500
Common stock issued for preferred dividends		82,916
Convertible debt exchanged for convertible preferred stock		300,000
Incremental value from warrant modifications		163,654
Fair value of common stock issued for services		214,192
Issuance of convertible preferred stock for board fees		84,750
Beneficial conversion feature on convertible preferred stock		1,495,415
Dividends earned on convertible preferred stock		$ 143,771
Accrued dividends on preferred stock	$ 23,194
Issuance of common stock for investment in available-for-sale equity securities	399,547
Unrealized loss from available-for-sale equity securities	105,025
Debt discount from derivative liability	6,819,730
Extension fees added to principal	84,000
Prepayment penalty and accrued interest enrolled into debt principal	$ 48,950

Business Overview

Business Overview	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	(1) Business Overview Pressure Biosciences, Inc. (“we”, “our”, “the Company”) is focused on solving the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by scientists worldwide working in biological life sciences research. Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming, and in our belief, one of the most error-prone steps of scientific research. It is a widely-used laboratory undertaking, the requirements of which drive what we believe is a large and growing worldwide market. We have developed and patented a novel, enabling technology platform that can control the sample preparation process. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (35,000 psi or greater) to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. Our pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels - at controlled temperatures and specific time intervals - to rapidly and repeatedly control the interactions of bio-molecules, such as DNA, RNA, proteins, lipids, and small molecules. Our laboratory instrument, the Barocycler®, and our internally developed consumables product line, including PULSE (Pressure Used to Lyse Samples for Extraction) Tubes, other processing tubes, and application specific kits (which include consumable products and reagents) together make up our PCT Sample Preparation System, or PCT SPS. In 2015, together with an investment bank, we formed a subsidiary called Pressure BioSciences Europe (“PBI Europe”) in Poland. We have 49% ownership interest with the investment bank retaining 51%. As of now, PBI Europe does not have any operating activities but is expected to commence operations in 2016. Therefore, we don’t have control of the subsidiary and did not consolidate in our financial statements. PBI Europe did not have any operations in 2015.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2015
Going Concern
Going Concern	(2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of December 31, 2015, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings in the past and as described in Note 6, completed debt financing subsequent to December 31, 2015. We have financing efforts in place to continue to raise cash through debt and equity offerings. Management has developed a plan to continue operations. This plan includes obtaining equity or debt financing. During the year ended December 31, 2015 we received 6,822,255 net proceeds, in additional convertible and non-convertible debt. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. We need substantial additional capital to fund normal operations in future periods. In the event that we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects. These financial statements do not include any adjustments that might result from this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(3) Summary of Significant Accounting Policies i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation. ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded, beneficial conversion features and derivative liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used. iii. Revenue Recognition Revenue is recognized when realized or when realizable and earned when all the following criteria have been met: persuasive evidence of an arrangement exists; goods were shipped, delivery of service has occurred and risk of loss has passed to the customer; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured. Our current instruments, the Barocycler NEP3229 and NEP2320, require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Product revenue related to current Barocycler instrumentation is recognized upon shipment of the unit, or in the case where the customer requests installation and training, the completion of the installation and introductory training process of the instrumentation at the customer location, for domestic installations. Product revenue related to sales of PCT instrumentation to our foreign distributors is recognized upon shipment through a common carrier. We provide for the expected costs of warranty upon the recognition of revenue for the sales of our instrumentation. Our sales arrangements do not provide our customers with a right of return. Product revenue related to the HUB440 and our consumable products such as PULSE Tubes, MicroTubes, and application specific kits is recorded upon shipment through a common carrier. Shipping costs are included in sales and marketing expense. Any shipping costs billed to customers are recognized as revenue. The Company applies ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. The Company currently records revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for our lease agreements under the operating method. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when qualifying expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and the Company’s service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying deliverables. Revenue from service contracts is recorded ratably over the length of the contract. Our transactions sometimes involve multiple elements (i.e., products and services). Revenue under multiple element arrangements is recognized in accordance with FASB ASC 605-25 Multiple-Element Arrangements (“ASC 605”) iv. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents. v. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life. vi. Inventories Inventories are valued at the lower of cost (average cost) or market (sales price). The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: 2015 2014 Raw materials $ 310,367 $ 304,928 Finished goods 778,004 595,624 Inventory reserve (50,000 ) (50,000 ) Total $ 1,038,371 $ 850,552 vii. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets. viii. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over sixteen years. We perform an annual review of our intangible assets for impairment. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. As of December 31, 2015 and 2014, the outstanding balance for intangible assets is zero. ix. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment x. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2015 and 2014, we determined that no allowance against accounts receivable was necessary. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: 2015 2014 Top Five Customers 38 % 32 % Federal Agencies 23 % 6 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2015 2014 Top Five Customers 93 % 86 % Federal Agencies 1 % 9 % Product Supply BIT Group USA, formerly Source Scientific, LLC, has been our sole contract manufacturer for all of our PCT instrumentation. Until we develop a broader network of manufacturers and subcontractors, obtaining alternative sources of supply or manufacturing services could involve significant delays and other costs and challenges, and may not be available to us on reasonable terms, if at all. The failure of a supplier or contract manufacturer to provide sufficient quantities, acceptable quality and timely products at an acceptable price, or an interruption of supplies from such a supplier could harm our business and prospects. Investment in Available-For-Sale Equity Securities As of December 31, 2015, we held 601,500 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We exchanged 1,000,000 shares of our common stock for the 601,500 shares from Everest. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities” xi. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: 2015 2014 Numerator: Net loss $ (7,415,298 ) $ (4,612,540 ) Beneficial conversion feature for preferred stock - (1,495,415 ) Preferred dividends accrued (23,194 ) (143,771 ) Net loss applicable to common shareholders $ (7,438,492 ) $ (6,251,726 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 20,726,205 14,264,753 Loss per common share - basic and diluted $ (0.36 ) $ (0.44 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: 2015 2014 Stock options 5,571,250 3,406,250 Convertible debt 19,689,286 5,453,571 Common stock warrants 29,227,664 19,182,201 Convertible preferred stock: Series D Convertible Preferred 750,000 750,000 Series G Convertible Preferred 865,700 865,700 Series H Convertible Preferred 1,000,000 1,000,000 Series H2 Convertible Preferred 2,100,000 2,100,000 Series J Convertible Preferred 3,546,000 3,546,000 Series K Convertible Preferred 11,416,000 11,416,000 74,165,900 47,719,722 xii. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2015 and 2014, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2015 and 2014. xiii. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee awards are accounted for under ASC 718 where the awards are valued at grant date. Awards given to nonemployees are accounted for under ASC 505 where the awards are valued at earlier of commitment date or completion of services. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the years ended December 31, 2015 and 2014: Assumptions Non-Employee Board Members CEO, other Officers and Employees Expected life 6.0 (yrs) 6.0 (yrs) Expected volatility 116.32%-141.15 % 116.32%-141.15 % Risk-free interest rate 0.65%-2.54 % 0.65%-2.54 % Forfeiture rate 5.00 % 5.00 % Expected dividend yield 0.0 % 0.0 % We recognized stock-based compensation expense of $208,989 and $101,125 for the years ended December 31, 2015 and 2014, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying Consolidated Statements of Operations for the years ended December 31: 2015 2014 Research and development $ 50,617 $ 30,550 Selling and marketing 32,704 19,792 General and administrative 125,668 50,783 Total stock-based compensation expense $ 208,989 $ 101,125 During the years ended December 31, 2015 and 2014, the total fair value of stock options awarded was $598,582 and $401,617, respectively. As of December 31, 2015, the total estimated fair value of unvested stock options to be amortized over their remaining vesting period was $740,117. The non-cash, stock based compensation expense associated with the vesting of these options will be $342,000 in 2016, $198,680 in 2017, and $199,437 in 2018. xiv. Advertising Advertising costs are expensed as incurred. We incurred $12,291 in 2015 with none incurred in 2014 for advertising. xv. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Short-term and long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value. xvi. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1 and that its financial liabilities are currently all classified within Level 3 in the fair value hierarchy. The following tables set forth the Company’s financial assets and financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015 and December 31, 2014. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Fair value measurements at December 31, 2015 using: December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 294,522 294,522 - - Total Financial Assets $ 294,522 $ 294,522 $ - $ - December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 173,526 - - $ 173,526 Warrants Issued with Convertible Debt 3,122,450 - - 3,122,450 Conversion Option Derivative Liabilities 3,940,791 - - 3,940,791 Total Derivatives $ 7,236,767 $ - $ - $ 7,236,767 Fair value measurements at December 31, 2014 using: Quoted prices in active Significant other Significant unobservable markets observable inputs inputs December 31, 2014 (Level 1) (Level 2) (Level 3) Series D Preferred Stock Purchase Warrants $159,875 - - $159,875 Conversion Option Liabilities 590,341 - - 590,341 Total Derivatives $750,216 $ - $ - $750,216 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: January 1, 2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities December 31, 2015 Series D Preferred Stock Purchase Warrants $ 159,875 $ - $ 13,651 $ - $ 173,526 Warrants Issued with Convertible Debt - 2,320,021 802,429 - 3,122,450 Conversion Option Derivative Liabilities 590,341 5,305,185 600,445 (2,555,180 ) 3,940,791 Total Derivatives $ 750,216 $ 7,625,206 $ 1,416,525 $ (2,555,180 ) $ 7,236,767 January 1, 2014 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities December 31, 2014 Series D Preferred Stock Purchase Warrants $ 344,570 $ - $ 145,710 $ (330,405 ) $ 159,875 Conversion Option Liabilities 356,197 898,684 (344,202 ) (320,338 ) 590,341 Total Derivatives $ 700,767 $ 898,684 $ (198,492 ) $ (650,743 ) $ 750,216 The issuance fair value for 2015 includes the “day 1” derivative loss on the conversion option derivative liabilities of $805,476 which are included in “change in fair value of derivative liabilities” in the consolidated statement of operations. The fair value of the derivative liabilities were determined using a binomial pricing model. The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2014 Warrants revalued at December 31, 2015 Expected life (in months) 60.0 22.0 11.0 Expected volatility 104.5 % 116.0 % 104.9 % Risk-free interest rate 0.875 % 0.58 % 0.65 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.15 $ 0.16 There were no warrants issued in 2014 with Convertible Debt. The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt in 2015 reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2015 Expected life (in months) 60.0 55.0-60.0 Expected volatility 118.3-120.1 % 136.3-141.6 % Risk-free interest rate 1.48-1.69 % 1.29-1.76 % Exercise price $ 0.40 $ 0.40 Fair value per warrant $ 0.19-$0.21 $ 0.30 The 2015 assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at December 31, 2015 Expected life (in months) 6-24 0-18 18-24 Expected volatility 104.2-153.8 % 86.9%-142.2 % 112.2-114.7 % Risk-free interest rate 0.05-0.99 % 0.01-0.72 % 1.06 % Exercise price $0.10-$0.35 $0.10-$0.25 $ 0.28 Fair value per conversion option $0.09-$0.28 $0.07-$0.26 $0.14-$0.33 The 2014 assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value Conversion options revalued at December 31, 2014 Expected life (in months) 6-24 1-32 Expected volatility 104.4-206.2 % 77.4-154.1 % Risk-free interest rate 0.05-0.99 % 0.03-.0.88 % Exercise price $0.13-$0.45 $0.14-0.35 Fair value per conversion option $0.15-$0.29 $0.00-$0.19 xvii. Recently Issued Accounting Standards In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. ASU 2015-03 does not change the recognition and measurement requirements for debt issuance costs. The Company early-adopted ASU 2015-03 as of the end of its Fiscal 2015, and applied its provisions retrospectively. The adoption of ASU 2015-03 resulted in the reclassification of approximately $888,000 unamortized debt issuance costs related to the Company's Senior Notes (see Note 8) from other non-current assets to long-term debt within its consolidated balance sheets as of December 31, 2015. Other than this reclassification, the adoption of ASU 2015-03 and other new pronouncements that have been issued did not have an impact on the Company's consolidated financial statements.

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment, net	(4) Property and Equipment, net Property and equipment as of December 31, 2015 and 2014 consisted of the following components: December 31, 2015 2014 Laboratory and manufacturing equipment $ 226,081 $ 226,081 Office equipment 158,872 149,459 Leasehold improvements 8,117 8,117 PCT collaboration, demonstration and leased systems 461,858 461,858 Total property and equipment 854,928 845,515 Less accumulated depreciation (834,779 ) (809,490 ) Net book value $ 20,149 $ 36,025 Depreciation expense for the years ended December 31, 2015 and 2014 was $25,288 and $29,213, respectively.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	(5) Intangible Assets, net Intangible assets as of December 31, 2015 reflect the purchase price attributable to patents in connection with the 1998 acquisition of BioSeq, Inc. and the PCT business. Acquired PCT patents were being amortized to expense on a straight-line basis at the rate of $48,632 per year over their estimated remaining useful lives of approximately 6 years. Intangible assets at December 31, 2015 and 2014 consisted of the following: 2015 2014 PCT Patents $ 778,156 $ 778,156 Less accumulated amortization (778,156 ) (778,156 ) Net book value $ - $ - Amortization expense for the year ended December 31, 2014 was $36,498, at which time the assets were fully amortized.

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Retirement Plan	(6) Retirement Plan We provide all of our employees with the opportunity to participate in our retirement savings plan. Our retirement savings plan has been qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the plan through payroll deductions within statutory limitations and subject to any limitations included in the plan. During 2015 and 2014 we contributed $22,098 and $10,022, respectively, in the form of discretionary Company-matching contributions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	(7) Income Taxes Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2015 and 2014, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2015 and 2014. We did not record an income tax benefit or provision for the years ended December 31, 2015 and 2014. Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2015 and December 31, 2014 are as follows: 2015 2014 Current deferred taxes Inventories $ 19,640 $ 19,640 Other accruals 23,714 21,818 Less: valuation allowance (43,354 ) (41,458 ) Total current deferred tax assets $ - $ - Long term deferred taxes: Accelerated tax depreciation $ 14,134 $ 12,162 Non-cash, stock-based compensation, nonqualified 562,426 440,614 Goodwill and intangibles - - Operating loss carry forwards and tax credits 12,028,900 9,720,260 Less: valuation allowance (12,605,460 ) (10,173,036 ) Total long term deferred tax assets (liabilities), net - - Total net deferred tax liabilities $ - $ - A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. Accordingly, a valuation allowance was established in 2015 and 2014 for the full amount of our deferred tax assets due to the uncertainty of realization. We believe based on our projection of future taxable operating income for the foreseeable future, it is more likely than not that we will not be able to realize the benefit of the deferred tax asset at December 31, 2015. We have net operating loss carry-forwards for federal income tax purposes of $26,752,000 as of December 31, 2015. Included in these numbers are loss carry-forwards that were obtained through the acquisition of BioSeq, Inc. and are subject to Section 382 NOL limitations. These net operating loss carry-forwards expire at various dates from 2018 through 2036. We had net operating loss carry-forwards for state income tax purposes of approximately $20,895,000 at December 31, 2015. These net operating loss carry-forwards expire at various dates from 2016 through 2036. We have research and development tax credit carry-forwards for federal income tax purposes of approximately $1,019,000 as of December 31, 2015 and research and development tax credit carry-forwards for state income tax purposes of approximately $165,000 as of December 31, 2015. The federal credit carry-forwards expire at various dates from 2016 through 2036. The state credit carry-forwards expire at various dates from 2023 through 2031. In addition, we have federal alternative minimum tax credit carry-forwards for federal income tax purposes of approximately $217,000 as of December 31, 2015. These credits do not expire. Our effective income tax (benefit) provision rate was different than the statutory federal income tax (benefit) provision rate as follows for the years ended December 31: 2015 2014 Federal tax provision rate 34 % 34 % Permanent differences (12 )% (2 )% State tax expense 0 % 0 % Refundable AMT and R&D tax credit 0 % 0 % Net operating loss carry back 0 % 0 % Valuation allowance (23 )% (32 )% Effective income tax provision 0 % 0 %

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(8) Commitments and Contingencies Operating Leases Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $4,800 per month, on a lease extension, signed on December 29, 2015, that expires December 31, 2016, for our corporate office. On November 1, 2014 we signed a lease for lab space in Medford, MA. We subsequently expanded our space in Medford. The lease expires December 30, 2017 and requires monthly payments of $5,385 subject to annual cost of living increases. Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2015: 2016 $ 122,220 Thereafter 64,620 Total minimum payments required $ 186,840 Royalty Commitments BioMolecular Assays, Inc. In 1996, we acquired our initial equity interest in BioSeq, Inc., which at the time was developing our original pressure cycling technology. BioSeq, Inc. acquired its pressure cycling technology from BioMolecular Assays, Inc. under a technology transfer and patent assignment agreement. In 1998, we purchased all of the remaining outstanding capital stock of BioSeq, Inc., and at such time, the technology transfer and patent assignment agreement was amended to require us to pay BioMolecular Assays, Inc. a 5% royalty on our sales of products or services that incorporate or utilize the original pressure cycling technology that BioSeq, Inc. acquired from BioMolecular Assays, Inc. We are also required to pay BioMolecular Assays, Inc. 5% of the proceeds from any sale, transfer or license of all or any portion of the original pressure cycling technology. These payment obligations terminate in 2016. During the fiscal years ended December 31, 2015 and 2014, we incurred $31,301 and $31,835 in royalties, respectively. In connection with our acquisition of BioSeq, Inc., we licensed certain limited rights to the original pressure cycling technology back to BioMolecular Assays, Inc. This license is non-exclusive and limits the use of the original pressure cycling technology by BioMolecular Assays, Inc. solely for molecular applications in scientific research and development and in scientific plant research and development. BioMolecular Assays, Inc. is required to pay us a royalty equal to 20% of any license or other fees and royalties, but not including research support and similar payments, it receives in connection with any sale, assignment, license or other transfer of any rights granted to BioMolecular Assays, Inc. under the license. BioMolecular Assays, Inc. must pay us these royalties until the expiration of the patents held by BioSeq, Inc. in 1998, which we anticipate will be 2016. We have not received any royalty payments from BioMolecular Assays, Inc. under this license. Battelle Memorial Institute In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“ Battelle Target Discovery Inc . In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“ TDI TDI reagents In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We recorded $22,000 of minimum royalty income in 2015 but none in 2014. Severance and Change of Control Agreements Each of Mr. Schumacher, and Drs. Ting, Lazarev, and Lawrence, executive officers of the Company, are entitled to receive a severance payment if terminated by us without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination. Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general; and particularly in the occurrence of a change in control, as a disincentive to the control change.

Convertible Debt and Other Debt

Convertible Debt and Other Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	(9) Convertible Debt We have entered into various convertible debentures. The convertible debentures have terms ranging from 12 to 24 months and subject to annual interest rates ranging from 2% to 9%. The proceeds received are net of fees. The lenders charge interest per annum based on the principal balance. The lenders have the right, at any time after 180 days from the issue date to convert any or part of the outstanding and unpaid principal and interest into shares of the Company’s common stock based on a volume weighted average price of the closing prices of the Company’s shares during various periods prior to conversion subject to adjustments for stock splits, stock dividends or rights offerings. The Company shall have the right to prepay the debenture for a payment of the outstanding principal plus unpaid interest at any time on or before six months after the effective date. If the Company chooses to prepay it will incur pre-payment penalties ranging from 9.5% to 38% of the principal balance. The Company is required to reserve shares of common stock for full conversion of these debentures. The maturity dates range from six months to two years after the effective date of the payment. The convertible debt as of December 31, 2015 are secured by the assets of the Company. The Company determined that the conversion feature met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature on each debt agreement and accounted for it as a derivative liability. The fair value of the conversion feature was accounted for as a note discount and will be amortized to interest expense over the life of the loan. The fair value of the conversion feature was reflected in the conversion option liability line in the consolidated balance sheets. We will continue to classify the fair value of the conversion options as a liability until the conversion options are exercised, expire or are amended in a way that would no longer require these conversion options to be classified as a liability, whichever comes first. The proceeds from these convertible debts were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in allocations to the convertible option and accounted for as a liability in the Company’s consolidated balance sheets. In accordance with the provisions of ASC 815-40, the gross proceeds are offset by debt discounts, which are amortized to interest expense over the expected life of the debt. In connection with the senior secured convertible debentures issued in our still open $5 million private placement, we also issued warrants to the lenders to purchase an aggregate 8,767,857 shares of the Common Stock, at an exercise price of $0.40 per share, expiring five years after the issuance date. ASC 470-20 states that the proceeds from the issuance of debt with detachable stock warrants should be allocated between the debt and warrants on the basis of their relative fair market values. The debt discount will be amortized to interest expense over the two-year term of these loans. The convertible debentures and warrants issued in connection with the convertible debentures are classified as derivative liabilities because the convertible debentures and warrants are entitled to certain rights in subsequent financings and these instruments contain “down-round protection” and therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging, (“ASC 815”). Since “down-round protection” is not an input into the calculation of the fair value of the convertible debentures and warrants, the instruments cannot be considered indexed to the Company’s own stock, which is a requirement for the scope exception as outlined under ASC 815. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $1,933,375 to the total warrants out of the gross proceeds of $4,910,000 at issuance date. The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. We will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first. The specific terms of the $5.4 million PIPE convertible debentures and outstanding balances as of December 31, 2015 are listed in the tables below. Fixed Rate Convertible Notes Inception Date Term Loan Amount Outstanding Balance Original Issue Discount Interest Rate Deferred Finance Fees Discount related to Fair value of conversion feature and warrants Prepayment Penalty July 22, 2015 24 months $ 2,180,000 $ 2,180,000 $ 218,000 1 10 % $ 388,532 $ 2,163,074 20 % September 25, 2015 24 months 1,100,000 1,100,000 110,000 1 10 % 2 185,956 1,022,052 20 % October 2, 2015 24 months 150,000 150,000 15,000 1 10 % 2 26,345 140,832 20 % October 6, 2015 24 months 30,000 30,000 3,000 1 10 % 2 5,168 26,721 20 % October 14, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,954 49,377 20 % November 2, 2015 24 months 250,000 250,000 25,000 1 10 % 2 43,079 222,723 20 % November 10, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,790 46,984 20 % November 12, 2015 24 months 215,000 215,000 21,500 1 10 % 2 38,518 212,399 20 % November 20, 2015 24 months 200,000 200,000 20,000 1 10 % 2 37,185 200,000 20 % December 4, 2015 24 months 170,000 170,000 17,000 1 10 % 2 37,352 170,000 20 % December 11, 2015 24 months 360,000 360,000 36,000 1 10 % 2 75,449 360,000 20 % December 18, 2015 24 months 55,000 55,000 5,500 1 10 % 2 11,714 55,000 20 % December 31, 2015 24 months 100,000 100,000 10,000 1 10 % 2 20,634 100,000 20 % $ 4,910,000 $ 4,910,000 $ 491,000 $ 887,676 $ 4,769,162 1 The original issue discount is reflected in the first year. 2 The annual interest starts accruing in the second year. Deferred finance fees include cash commissions amounting to $501,000 and the fair value of the 1,689,286 warrants issued to the placement agent amounting to $386,676. For the year ended December 31, 2015, the Company recognized amortization expense related to the debt discounts indicated above of $924,180. The unamortized debt discounts as of December 31, 2015 related to the convertible debentures amounted to $5,223,658. As of December 31, 2015, the Company also had an outstanding convertible note with a third party amounting to $100,000. The note is convertible at a fixed rate of $0.25 and matures in July 2016. Variable Rate Convertible Notes Inception Date Term Loan Amount Interest Rate Fees Fair value of conversion feature Prepayment Penalty Discount to VWAP Share reserve requirement December 4, 2013 12 months $ 223,000 * 4 % $ 10,000 $ 59,903 20 % - February 2, 2015 12 months 100,000 * 4 % 5,000 62,219 19-33 % - February 2, 2015 12 months 120,000 * 4 % 5,000 74,663 19-33 % - February 22, 2015 six months 100,000 * 4 % - 61,597 19-33 % - February 25, 2015 12 months 112,500 * 8 % 4,000 312,847 19-33 % - March 4, 2015 12 months 52,500 * 4 % 2,500 53,213 19-38 % - March 6, 2015 12 months 236,250 * 2 % 33,900 212,918 19-35 % - March 17, 2015 24 months 50,000 * 4 % - 64,382 19-33 % - March 20, 2015 12 months 25,000 * 4 % - 25,077 19-33 % - March 26, 2015 12 months 150,000 * 6 % 2,000 164,501 19-37.5 % - March 27, 2015 12 months 52,500 * 4 % 2,500 57,502 19-38 % - March 27, 2015 12 months 100,000 * 8 % 8,000 154,359 19-38 % - April 1, 2015 12 months 100,000 * 8 % - 155,793 25-35 % 40% of 10 days - April 20, 2015 12 months 81,250 * 4 % 6,563 117,679 20 % - April 28, 2015 12 months 54,050 * 9 % 4,050 35,143 20 % - May 12, 2015 12 months 107,764 * 4 % 7,763 145,527 20 % - May 20, 2015 12 months 100,000 * 4 % - 92,715 9.5-33 % 45% of 10 days 3,000,000 May 26, 2015 12 months 60,000 * 8 % 3,500 79,287 10-35 % - June 23, 2015 12 months 126,000 * 4 % 6,000 108,297 19-33 % 35% of 15 days 3,101,000 June 24, 2015 24 months 50,000 * 4 % - 54,511 19-33 % 35% of 10 days 1,000,000 July 2, 2015 12 months 52,500 * 4 % 2,500 54,297 19-33 % 35% of 15 days 1,500,000 July 2, 2015 12 months 52,500 * 4 % 2,500 54,297 19-33 % 35% of 15 days 1,000,000 $ 2,105,814 $ 105,776 $ 2,200,727 9,601,000 * The loans above either had outstanding balances as of December 31, 2014 or were issued in 2015 and subsequently paid off in 2015. The following table provides a summary of the changes in convertible debt, net of unamortized discount, during 2015: 2015 Balance at January 1, $ 1,004,513 Issuance of convertible debt, face value 7,287,317 Original issue discount (567,780 ) Debt discount from derivative liabilities (embedded conversion option and warrants) (6,433,054 ) Deferred financing fees (887,676 ) Repayment of convertible debt (2,653,990 ) Conversion of convertible debt into common stock (382,054 ) Fees added to principal debt 84,000 Settlement of prepayment penalty (96,023 ) Amortization of debt discount to interest expense through December 31, 2,922,089 Balance at December 31, 277,342 Less: current portion 100,000 Convertible debt, long-term portion $ 177,342 Other Notes On June 6, 2014, we signed a Merchant Agreement with On Deck Capital. Under the agreement we received $150,000 in exchange for rights to all customer receipts until On Deck Capital is paid $190,499, to be collected at the rate of $756 per business day. The payments are secured by essentially all tangible assets of the Company. The Company paid On Deck Capital $3,750 in fees related to this transaction. The note was paid off in its entirety in 2015. On January 15, 2015 we signed a Merchant Agreement with a lender. Under the agreement, we received $150,000 in exchange for rights to all customer receipts until the lender was paid $187,500, which was collected at the rate of $744 per business day. The payments were secured by essentially all tangible assets of the Company. $67,925 of the proceeds were used to pay off the outstanding balance of a previous loan from this lender. The Company paid $1,875 in fees in connection with this loan. The note was paid off in its entirety prior to December 31, 2015. On January 29, 2015 we signed a Merchant Agreement with a lender. Under the agreement, we received $200,000 in exchange for rights to all customer receipts until the lender was paid $278,000, which was collected at the rate of $1,985 per business day. The payments were secured by essentially all tangible assets of the Company. The Company paid $999 in fees in connection with this loan. The note was paid off in its entirety prior to December 31, 2015. On March 17, 2015 we signed a Merchant Agreement with a lender. Under the agreement, we received $50,000 in exchange for rights to all customer receipts until the lender was paid $67,450, which was collected at the rate of $559 per business day. The payments were secured by essentially all tangible assets of the Company. The Company paid $999 in fees in connection with this loan. The note was paid off in its entirety prior to December 31, 2015. On May 29, 2015 we signed a Merchant Agreement with a lender. Under the agreement, we received $100,000 in exchange for rights to all customer receipts until the lender was paid $132,000, which was collected at the rate of $1,098 per business day. The Company paid $3,999 in fees in connection with this loan. The note was paid off in its entirety prior to December 31, 2015. On August 28, 2015 we signed a Merchant Agreement with a lender. Under the agreement, we received $300,000 in exchange for rights to all customer receipts until the lender is paid $384,000, to be collected at the rate of $2,560 per business day. The payments are not secured. On the closing date, $131,710 of the proceeds were used to pay off the outstanding balances of two existing Notes. The Company paid $6,000 in fees in connection with this loan. The outstanding balance is recorded as other debt on the balance sheet. During the year ended December 31, 2015, we signed three ninety-day notes with an investor. Under the terms of the notes, the Company received a total of $600,000. The investor converted these loans, plus $60,000 in accrued interest into the Company’s $5 million PIPE offering on July 21, 2015. There was no gain or loss on the conversion. During the year ended December 31, 2015, the Company made payments of $587,949 in total on the non-convertible debt from non-related parties. Related Party Notes During the year ended December 31, 2015, the Company received advances from certain officers of the Company amounting to $6,300 and made payments of $12,300. These advances are non-interest bearing and payable on demand. As of December 31, 2015 there are no outstanding notes to related parties.

Stockholders' (Deficit)

Stockholders' (Deficit)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Stockholders' (Deficit)	(10) Stockholders’ (Deficit) Preferred Stock We are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock: 1) 20,000 shares have been designated as Series A Junior Participating Preferred Stock (“ Junior A 2) 313,960 shares have been designated as Series A Convertible Preferred Stock (“ Series A 3) 279,256 shares have been designated as Series B Convertible Preferred Stock (“ Series B 4) 88,098 shares have been designated as Series C Convertible Preferred Stock (“ Series C 5) 850 shares have been designated as Series D Convertible Preferred Stock (“ Series D 6) 500 shares have been designated as Series E Convertible Preferred Stock (“Series E”) 7) 240,000 shares have been designated as Series G Convertible Preferred Stock (“ Series G 8) 10,000 shares have been designated as Series H Convertible Preferred Stock (“ Series H 9) 21 shares have been designated as Series H2 Convertible Preferred Stock (“ Series H2 10) 6,250 shares have been designated as Series J Convertible Preferred Stock (“ Series J 11) 15,000 shares have been designated as Series K Convertible Preferred Stock (“ Series K As of December 31, 2015 and 2014, there were no shares of Junior A, and Series A, B, C, E, and H1 issued and outstanding. Series D Convertible Preferred Stock On November 11, 2011, we completed a registered direct offering, pursuant to which we sold an aggregate of 843 units for a purchase price of $1,000 per unit, resulting in gross proceeds to us of $843,000 (the “ Series D Series D Unit Series D Convertible Preferred Stock Series D Warrant The proceeds from the sale of each Series D Unit were allocated between the Series D Convertible Preferred Stock and the Series D Warrants based on the residual method. The estimated fair value of the Series D Warrants was determined using a binomial formula, resulting in an allocation of the gross proceeds of $283,725 to the total warrants issued. The allocation of the gross proceeds to the Series D Convertible Preferred Stock was $559,275. In accordance with the provisions of ASC 470-20, an additional adjustment between Additional Paid in Capital and Accumulated Deficit of $530,140 was recorded to reflect an implicit non-cash dividend related to the allocation of proceeds between the stock and warrants issued. The $530,140 represents the value of the adjustment to additional paid in capital related to the beneficial conversion feature of the Series D Convertible Preferred Stock. The value adjustment was calculated by subtracting the fair market value of the underlying common stock on November 10, 2011 issuable upon conversion of the Series D Convertible Preferred Stock from the fair market value of the Series D Convertible Preferred Stock as determined when the Company performed a fair market value allocation of the proceeds to the Series D Convertible Preferred Stock and warrants. The warrants are recorded as a liability. See “Warrant Derivative Liability” below. The Series D Convertible Preferred Stock will rank senior to the Company’s common stock and Series C Convertible Preferred Stock with respect to payments made upon liquidation, winding up or dissolution. Upon any liquidation, dissolution or winding up of the Company, after payment of the Company’s debts and liabilities, and before any payment is made to the holders of any junior securities, the holders of Series D Convertible Preferred Stock will first be entitled to be paid $1,000 per share subject to adjustment for accrued but unpaid dividends. We may not pay any dividends on shares of common stock unless we also pay dividends on the Series D Convertible Preferred Stock in the same form and amount, on an as-if-converted basis, as dividends actually paid on shares of our common stock. Except for such dividends, no other dividends may be paid on the Series D Convertible Preferred Stock. Each share of Series D Convertible Preferred Stock is convertible into 1,538.46 shares of common stock (based upon an initial conversion price of $0.65 per share) at any time at the option of the holder, subject to adjustment for stock splits, stock dividends, combinations, and similar recapitalization transactions (the “ Series D In addition, in the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares of common stock, then following such event, the holders of the Series D Convertible Preferred Stock will be entitled to receive upon conversion of the Series D Convertible Preferred Stock the same kind and amount of securities, cash or property which the holders of the Series D Convertible Preferred Stock would have received had they converted the Series D Convertible Preferred Stock immediately prior to such fundamental transaction. The holders of Series D Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except that the holders of Series D Convertible Preferred Stock may vote separately as a class on any matters that would (i) amend, our Restated Articles of Organization, as amended, in a manner that adversely affects the rights of the Series D Convertible Preferred Stock, (ii) alter or change adversely the powers, preferences or rights of the Series D Convertible Preferred Stock or alter or amend the certificate of designation, (iii) authorize or create any class of shares ranking as to dividends, redemption or distribution of assets upon liquidation senior to, or otherwise pari passu with, the Series D Convertible Preferred Stock, or (iv) increase the number of authorized shares of Series D Convertible Preferred Stock. If, within 12 months of the initial issuance of the Series D Convertible Preferred Stock, we issue any common stock, common stock equivalents, indebtedness or any combination thereof (a “ Subsequent Financing Series D Warrants The Series D Warrants originally had an exercise price equal to $0.81 per share of common stock. In April 2012, the number of Series D Warrants increased by 530,406 to a total of 1,047,875 and each Series D Warrant had an exercise price reset to $0.40 per share of common stock. In December of 2013 the number of Series D Warrants increased by 628,733 to a total of 1,676,608 and each Series D Warrant had an exercise price reset to $0.25 per share of common stock. The Series D Warrants will be exercisable beginning on the six-month anniversary of the date of issuance and expire five years from the initial exercise date. The Series D Warrants permit the holder to conduct a “cashless exercise” at any time a registration statement registering, or the prospectus contained therein, is not available for the issuance of the shares of common stock issuable upon exercise of the Series D Warrant, and under certain circumstances at the expiration of the Series D Warrants. The exercise price and/or number of shares of common stock issuable upon exercise of the Series D Warrants are subject to adjustment for certain stock dividends, stock splits or similar capital reorganizations, as set forth in the Warrants. The exercise price is also subject to adjustment in the event that we issue any shares of common stock or common stock equivalents at a per share price that is lower than the exercise price for the Series D Warrants then in effect. Upon any such issuance, subject to certain exceptions, the exercise price will be reduced to the per share price at which such shares of common stock or common stock equivalents are issued and number of Series D Warrant shares issuable thereunder shall be increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, shall be equal to the aggregate exercise price prior to such adjustment. Unless waived under certain circumstance by the holder of a Series D Warrant, such holder may not exercise the Series D Warrant if upon such exercise the holder’s beneficial ownership of the Company’s common stock would exceed certain thresholds. In the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares of common stock, then following such event, the holders of the Series D Warrants will be entitled to receive upon exercise of the Series D Warrants the same kind and amount of securities, cash or property which the holders would have received had they exercised the Series D Warrants immediately prior to such fundamental transaction. Series G Convertible Preferred Stock On July 6 and November 15, 2012, we completed a private placement, pursuant to which we sold an aggregate of 145,320 units for a purchase price of $5.00 per unit (the “Series G Purchase Price”), resulting in gross proceeds to us of $726,600 (the “ Series G Private Placement Series G Unit Series G Each share of Series G Preferred Stock will receive a cumulative dividend at the annual rate of (i) four percent (4%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of less than $100,000, (ii) six percent (6%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of at least $100,000 but less than $250,000, and (iii) twelve percent (12%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of at least $250,000. Dividends accruing on the Series G Preferred Stock shall accrue from day to day until, and shall be paid within fifteen (15) days of, the first anniversary of, the original issue date of the Series G Preferred Stock; provided, however, if any shares of the Company’s Series E Preferred Stock are outstanding at such time, payment of the accrued dividends on the Series G Preferred Stock shall be deferred until no such shares of Series E Convertible Preferred Stock remain outstanding. The Company may pay accrued dividends on the Series G Preferred Stock in cash or in shares of its common stock equal to the volume weighted average price of the common stock as reported by the OTC QB Market for the ten (10) trading days immediately preceding the Series G’s first anniversary. At the election of the Company and upon required advanced notice, each share of Series G Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) if, after 6 months from the original issuance date of the Series G Preferred Stock, the common stock trades on the OTC QB Market (or other primary trading market or exchange on which the common stock is then traded) at a price equal to at least $0.75, for 7 out of 10 consecutive trading days with average daily trading volume of at least 10,000 shares, (ii) on or after the first anniversary of the original issuance date of the Series G Preferred Stock or (iii) upon completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $0.75, with aggregate gross proceeds to the Company of not less than $2.5 million. Unless waived under certain circumstances by the holder of the Series G Preferred Stock, such holder’s Series G Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. The holders of Series G Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series G Warrants The Series G Warrants issued in the Series G Private Placement had an exercise price equal to $0.50 per share and expired on July 6, 2015. Series H Convertible Preferred Stock On December 28, 2012 the Company amended the Articles of Incorporation to authorize 10,000 shares of Series H Convertible Preferred Stock. On January 4, 2013, the Company reported that it had entered into a securities purchase and exchange agreement with an investor, pursuant to which the Company agreed to exchange 1,000,000 shares of the Company’s common stock, par value $0.01 per share of common stock held by the investor for an aggregate of 10,000 shares of a newly created series of preferred stock, designated Series H Convertible Preferred Stock, par value $0.01 per share (the “ Series H Preferred Stock Series H2 Convertible Preferred Stock On December 23, 2014 the Company amended the Articles of Incorporation to authorize 21 shares of Series H2 Convertible Preferred Stock. On December 23, 2014, the Company reported that it had entered into a securities purchase and exchange agreement with an investor, pursuant to which the Company agreed to exchange 2,100,000 shares of the Company’s common stock, par value $0.01 per share of common stock held by the investor for an aggregate of 21 shares of a newly created series of preferred stock, designated Series H2 Convertible Preferred Stock, par value $0.01 per share (the “ Series H2 Preferred Stock Series J Convertible Preferred Stock On February 6, March 28 and May 20, 2013, the Company entered into a Securities Purchase with various individuals pursuant to which the Company sold an aggregate of 5,087.5 units for a purchase price of $400.00 per unit (the “Purchase Price”), or an aggregate Purchase Price of $2,034,700. Each unit purchased in the initial tranche consists of (i) one share of a newly created series of preferred stock, designated Series J Convertible Preferred Stock, par value $0.01 per share (the “Series J Convertible Preferred Stock”), convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 1,000 shares of common stock at an exercise price equal to $0.40 per share. The warrants expire three years from the issuance date. From the date of issuance of any shares of Series J Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series J Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series J Convertible Preferred Stock, dividends will accrue on each share of Series J Convertible Preferred Stock at an annual rate of (i) four percent (4%) of the Purchase Price on those shares of Series J Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased from the Company shares of Series J Convertible Preferred Stock with an aggregate Purchase Price of less than $250,000, and (ii) six percent (6%) of the Purchase Price on those shares of Series J Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased shares of Series J Convertible Preferred Stock with an aggregate purchase price of at least $250,000. Dividends accruing on the Series J Convertible Preferred Stock shall accrue from day to day until the earlier of the first anniversary of the date of issuance of such shares of Series J Convertible Stock, the voluntary conversion of any shares of Series J Convertible Preferred Stock, or the date of any mandatory conversion of the Series J Convertible Preferred Stock, and shall be paid, as applicable, within fifteen (15) days of the first anniversary of the original issue date of the Series J Convertible Preferred Stock, within five (5) days of the voluntary conversion of shares of the Series J Convertible Preferred Stock, or within five (5) days of the mandatory conversion of shares of the Series J Convertible Preferred Stock. The Company may pay accrued dividends on the Series J Convertible Preferred Stock in cash or, in the sole discretion of the Board of Directors of the Company, in shares of its common stock in accordance with a specified formula. Each share of Series J Convertible Preferred Stock is convertible into 1,000 shares of common stock at the option of the holder on or after the six-month anniversary of the issuance of such share, subject to adjustment for stock splits, stock dividends, recapitalizations and similar transactions (the “Conversion Ratio”). Unless waived under certain circumstances by the holder of Series J Convertible Preferred Stock, such holder’s shares of Series J Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. At the election of the Company and upon required advance notice, each share of Series J Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) on or after the six-month anniversary of the original issuance date of the Series J Convertible Preferred Stock, the common stock trades on the OTC QB Market (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $0.80 for 7 out of 10 consecutive trading days with average daily trading volume of at least 50,000 shares, (ii) on the first anniversary of the original issuance date of the Series J Convertible Preferred Stock or (iii) within three days of the completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $0.80, with aggregate gross proceeds to the Company of not less than $2.5 million. Unless waived under certain circumstances by the holder of the Series J Convertible Preferred Stock, such holder’s Series J Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. The holders of Series J Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series J Warrants The Warrants issued in the Private Placement have an exercise price equal to $0.40 per share, with a term expiring three years from the issuance date. The Warrants also permit the holder to conduct a “cashless exercise” at any time the holder of the Warrant is an affiliate of the Company. The exercise price and/or number of shares issuable upon exercise of the Warrants will be subject to adjustment for stock dividends, stock splits or similar capital reorganizations, as set forth in the Warrant agreement. Subject to the terms and conditions of the Warrants, at any time commencing six months from the closing date of the sale of Units under the Securities Purchase Agreement the Company has the right to call the Warrants for cancellation if the volume weighted average price of its common stock on the OTC QB Market (or other primary trading market or exchange on which the common stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for either (i) 10 consecutive trading days or (ii) 15 out of 25 consecutive trading days. Registration Rights Agreement In connection with the Private Placement, the Company has agreed that, if, at any time after February 1, 2014, the Company files a Registration Statement relating to an offering of equity securities of the Company (the “Registration Statement”), subject to certain exceptions, including a Registration Statement relating solely to an offering or sale of securities having an aggregate public offering price of less than $5,000,000, the Company shall include in the Registration Statement the resale of the shares of common stock underlying the Warrants. Shares of common stock issued upon conversion of Series J Convertible Preferred Stock or in payment of the dividend on the Series J Convertible Preferred Stock will not be registered and will not be subject to registration rights. This right is subject to customary conditions and procedures. Series K Convertible Preferred Stock On December 12, 2013, the Company entered into a Securities Purchase with various individuals pursuant to which the Company sold an aggregate of 4,000 units for a purchase price of $250.00 per unit (the “Purchase Price”), for an aggregate Purchase Price of $1,000,000. Each unit purchased in the initial tranche consists of (i) one share of a newly created series of preferred stock, designated Series K Convertible Preferred Stock, par value $0.01 per share (the “Series K Convertible Preferred Stock”), convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.3125 per share. The warrants expire three years from the issuance date. Of the $1,000,000 invested in the Private Placement, $572,044 was received in cash and $427,956 was from the conversion of outstanding indebtedness and interest. The Company incurred $43,334 of fees in conjunction with this private placement. The purchasers in the initial tranche of the private placement consisted of certain existing and new investors in the Company as well as all of the members of the Company’s Board of Directors. From the date of issuance of any shares of Series K Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series K Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series K Convertible Preferred Stock, dividends will accrue on each share of Series K Convertible Preferred Stock at an annual rate of (i) four percent (4%) of the Purchase Price on those shares of Series K Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased from the Company shares of Series K Convertible Preferred Stock with an aggregate Purchase Price of less than $100,000, and (ii) six percent (6%) of the Purchase Price on those shares of Series K Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased shares of Series K Convertible Preferred Stock with an aggregate purchase price of at least $100,000. Dividends accruing on the Series K Convertible Preferred Stock shall accrue from day to day until the earlier of the first anniversary of the date of issuance of such shares of Series K Convertible Stock, the voluntary conversion of any shares of Series K Convertible Preferred Stock, or the date of any mandatory conversion of the Series K Convertible Preferred Stock, and shall be paid, as applicable, within fifteen (15) days of the first anniversary of the original issue date of the Series K Convertible Preferred Stock, within five (5) days of the voluntary conversion of shares of the Series K Convertible Preferred Stock, or within five (5) days of the mandatory conversion of shares of the Series K Convertible Preferred Stock. The Company may pay accrued dividends on the Series K Convertible Preferred Stock in cash or, in the sole discretion of the Board of Directors of the Company, in shares of its common stock in accordance with a specified formula. Each share of Series K Convertible Preferred Stock is convertible into 1,000 shares of common stock at the option of the holder on or after the six-month anniversary of the issuance of such share, subject to adjustment for stock splits, stock dividends, recapitalizations and similar transactions (the “Conversion Ratio”). Unless waived under certain circumstances by the holder of Series K Convertible Preferred Stock, such holder’s shares of Series K Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. At the election of the Company and upon required advance notice, each share of Series K Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) on or after the six-month anniversary of the original issuance date of the Series K Convertible Preferred Stock, the common stock trades on the OTC QB Market (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $0.80 for 7 out of 10 consecutive trading days with average daily trading volume of at least 50,000 shares, (ii) on the first anniversary of the original issuance date of the Series K Convertible Preferred Stock or (iii) within three days of the completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $0.80, with aggregate gross proceeds to the Company of not less than $2.5 million. Unless waived under certain circumstances by the holder of the Series K Convertible Preferred Stock, such holder’s Series K Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. The proceeds from the sale of each Series K Unit were allocated between the Series K Convertible Preferred Stock and the Series K Warrants based on the relative fair value method. The estimated fair value of the Series K Warrants was determined using a Black-Scholes formula, resulting in an allocation of the gross proceeds of $271,422 to the total warrants issued. The allocation of the gross proceeds to the Series K Convertible Preferred Stock was $685,245, net of $43,334 in fees. In accordance with the provisions of ASC 470-20, an additional adjustment in the aggregate between Additional Paid in Capital and Accumulated Deficit of $1,495,415 was recorded for all tranches of Series K to reflect an implicit, deemed non-cash dividend related to the allocation of proceeds between the stock and warrants issued. The $1,495,415 represents the aggregate value of the adjustment to additional paid in capital related to the beneficial conversion feature of the Series K Convertible Preferred Stock. The value adjustment was calculated by subtracting the fair market value of the underlying common stock on the closing dates issuable upon conversion of the Series K Convertible Preferred Stock from the fair market value of the Series K Convertible Preferred Stock as determined when the Company performed a fair market value allocation of the proceeds to the Series K Convertible Preferred Stock and warrants. On January 29, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 4,875 units for a purchase price of $250.00 per unit or an aggregate Purchase Price of $1,218,750. This was the second tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the second tranche of the Private Placement consisted of certain existing and new investors in the Company, as well as all of the members of the Company’s board of directors. Each unit purchased in the second tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share, convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.3125 per share, with a term expiring on January 29, 2017. On February 28, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 1,854 units for a purchase price of $340.00 per unit or an aggregate Purchase Price of $630,360. This was the third tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the third tranche of the Private Placement consisted of certain existing and new investors in the Company. Each unit purchased in the third tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.425 per share, with a term expiring on February 28, 2017. On June 30, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 734 units for a purchase price of $300.00 per unit or an aggregate Purchase Price of $220,000. This was the fourth tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the fourth tranche of the Private Placement consisted of certain existing and new investors in the Company. Each unit purchased in the fourth tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.375 per share, with a term expiring on June 30, 2017. On November 12, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 1,052 units for a purchase price of $250.00 per unit or an aggregate Purchase Price of $263,000. This was the fifth tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the fourth tranche of the Private Placement consisted of certain existing and new investors in the Company. Each unit purchased in the fifth tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.3125 per share, with a term expiring on November 12, 2017. The Private Placement was originally expected to raise $1.5 million and close on or before January 31, 2014. On January 29, 2014, the Company’s Board of Directors voted to increase the subscription amount of the Private Placement by $718,750. The Board of Directors also voted to extend the Private Placement until February 28, 2014. On February 28, 2014 the Company’s Board of Directors voted to increase the subscription amount once again to a total of $3.5 million and extended the closing to April 4, 2014. On April 13, 2014 the Company’s Board of Directors voted to increase the subscription amount by $1 million, to a total of $4.5 million, and extended the closing to May 31, 2014. On July 7, 2014 the Company’s Board of Directors voted to extend the closing to August 15, 2014. Together with the initial tranche of $1,000,000 that closed on December 12, 2013, the second tranche of $1,218,750 that closed January 29, 2014, the third tranche of $630,360 that closed February 28, 2014, the fourth tranche of $220,000 that closed June 30, 2014, and the fifth tranche of $263,000 that closed November 12, 2014,the total consideration received by the Company in the Private Placement is $3,332,110, which is comprised of $2,511,404 in cash and $820,706 from the conversion of outstanding indebtedness and Board of Director

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	(11) Subsequent Events Since January 1, 2016, the Company received $1,419,667 in net proceeds from the sale of convertible debentures and $256,660 in net proceeds from short- term promissory notes. On various dates from January to March 2016 the Company issued 205,000 shares of restricted common stock to investor relations firms for services rendered. On January 12, 2016 SCIEX, a global leader in life science analytical technologies (Framingham, MA) and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), announced an exclusive co-marketing agreement with PBI to improve protein quantification in complex samples.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation	i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded, beneficial conversion features and derivative liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Revenue Recognition	iii. Revenue Recognition Revenue is recognized when realized or when realizable and earned when all the following criteria have been met: persuasive evidence of an arrangement exists; goods were shipped, delivery of service has occurred and risk of loss has passed to the customer; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured. Our current instruments, the Barocycler NEP3229 and NEP2320, require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Product revenue related to current Barocycler instrumentation is recognized upon shipment of the unit, or in the case where the customer requests installation and training, the completion of the installation and introductory training process of the instrumentation at the customer location, for domestic installations. Product revenue related to sales of PCT instrumentation to our foreign distributors is recognized upon shipment through a common carrier. We provide for the expected costs of warranty upon the recognition of revenue for the sales of our instrumentation. Our sales arrangements do not provide our customers with a right of return. Product revenue related to the HUB440 and our consumable products such as PULSE Tubes, MicroTubes, and application specific kits is recorded upon shipment through a common carrier. Shipping costs are included in sales and marketing expense. Any shipping costs billed to customers are recognized as revenue. The Company applies ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. The Company currently records revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for our lease agreements under the operating method. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when qualifying expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and the Company’s service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying deliverables. Revenue from service contracts is recorded ratably over the length of the contract. Our transactions sometimes involve multiple elements (i.e., products and services). Revenue under multiple element arrangements is recognized in accordance with FASB ASC 605-25 Multiple-Element Arrangements (“ASC 605”)
Cash and Cash Equivalents	iv. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents.
Research and Development	v. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life.
Inventories	vi. Inventories Inventories are valued at the lower of cost (average cost) or market (sales price). The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: 2015 2014 Raw materials $ 310,367 $ 304,928 Finished goods 778,004 595,624 Inventory reserve (50,000 ) (50,000 ) Total $ 1,038,371 $ 850,552
Property and Equipment	vii. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets.
Intangible Assets	viii. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over sixteen years. We perform an annual review of our intangible assets for impairment. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. As of December 31, 2015 and 2014, the outstanding balance for intangible assets is zero.
Long-Lived Assets	ix. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment
Concentrations	x. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2015 and 2014, we determined that no allowance against accounts receivable was necessary. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: 2015 2014 Top Five Customers 38 % 32 % Federal Agencies 23 % 6 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2015 2014 Top Five Customers 93 % 86 % Federal Agencies 1 % 9 % Product Supply BIT Group USA, formerly Source Scientific, LLC, has been our sole contract manufacturer for all of our PCT instrumentation. Until we develop a broader network of manufacturers and subcontractors, obtaining alternative sources of supply or manufacturing services could involve significant delays and other costs and challenges, and may not be available to us on reasonable terms, if at all. The failure of a supplier or contract manufacturer to provide sufficient quantities, acceptable quality and timely products at an acceptable price, or an interruption of supplies from such a supplier could harm our business and prospects. Investment in Available-For-Sale Equity Securities As of December 31, 2015, we held 601,500 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We exchanged 1,000,000 shares of our common stock for the 601,500 shares from Everest. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”
Computation of Loss per Share	xi. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: 2015 2014 Numerator: Net loss $ (7,415,298 ) $ (4,612,540 ) Beneficial conversion feature for preferred stock - (1,495,415 ) Preferred dividends accrued (23,194 ) (143,771 ) Net loss applicable to common shareholders $ (7,438,492 ) $ (6,251,726 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 20,726,205 14,264,753 Loss per common share - basic and diluted $ (0.36 ) $ (0.44 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: 2015 2014 Stock options 5,571,250 3,406,250 Convertible debt 19,689,286 5,453,571 Common stock warrants 29,227,664 19,182,201 Convertible preferred stock: Series D Convertible Preferred 750,000 750,000 Series G Convertible Preferred 865,700 865,700 Series H Convertible Preferred 1,000,000 1,000,000 Series H2 Convertible Preferred 2,100,000 2,100,000 Series J Convertible Preferred 3,546,000 3,546,000 Series K Convertible Preferred 11,416,000 11,416,000 74,165,900 47,719,722
Accounting for Income Taxes	xii. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2015 and 2014, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2015 and 2014.
Accounting for Stock-Based Compensation	xiii. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee awards are accounted for under ASC 718 where the awards are valued at grant date. Awards given to nonemployees are accounted for under ASC 505 where the awards are valued at earlier of commitment date or completion of services. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the years ended December 31, 2015 and 2014: Assumptions Non-Employee Board Members CEO, other Officers and Employees Expected life 6.0 (yrs) 6.0 (yrs) Expected volatility 116.32%-141.15 % 116.32%-141.15 % Risk-free interest rate 0.65%-2.54 % 0.65%-2.54 % Forfeiture rate 5.00 % 5.00 % Expected dividend yield 0.0 % 0.0 % We recognized stock-based compensation expense of $208,989 and $101,125 for the years ended December 31, 2015 and 2014, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying Consolidated Statements of Operations for the years ended December 31: 2015 2014 Research and development $ 50,617 $ 30,550 Selling and marketing 32,704 19,792 General and administrative 125,668 50,783 Total stock-based compensation expense $ 208,989 $ 101,125 During the years ended December 31, 2015 and 2014, the total fair value of stock options awarded was $598,582 and $401,617, respectively. As of December 31, 2015, the total estimated fair value of unvested stock options to be amortized over their remaining vesting period was $740,117. The non-cash, stock based compensation expense associated with the vesting of these options will be $342,000 in 2016, $198,680 in 2017, and $199,437 in 2018.
Advertising	xiv. Advertising Advertising costs are expensed as incurred. We incurred $12,291 in 2015 with none incurred in 2014 for advertising.
Fair Value of Financial Instruments	xv. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Short-term and long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value.
Fair Value Measurements	xvi. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1 and that its financial liabilities are currently all classified within Level 3 in the fair value hierarchy. The following tables set forth the Company’s financial assets and financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015 and December 31, 2014. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Fair value measurements at December 31, 2015 using: December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 294,522 294,522 - - Total Financial Assets $ 294,522 $ 294,522 $ - $ - December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 173,526 - - $ 173,526 Warrants Issued with Convertible Debt 3,122,450 - - 3,122,450 Conversion Option Derivative Liabilities 3,940,791 - - 3,940,791 Total Derivatives $ 7,236,767 $ - $ - $ 7,236,767 Fair value measurements at December 31, 2014 using: Quoted prices in active Significant other Significant unobservable markets observable inputs inputs December 31, 2014 (Level 1) (Level 2) (Level 3) Series D Preferred Stock Purchase Warrants $159,875 - - $159,875 Conversion Option Liabilities 590,341 - - 590,341 Total Derivatives $750,216 $ - $ - $750,216 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: January 1, 2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities December 31, 2015 Series D Preferred Stock Purchase Warrants $ 159,875 $ - $ 13,651 $ - $ 173,526 Warrants Issued with Convertible Debt - 2,320,021 802,429 - 3,122,450 Conversion Option Derivative Liabilities 590,341 5,305,185 600,445 (2,555,180 ) 3,940,791 Total Derivatives $ 750,216 $ 7,625,206 $ 1,416,525 $ (2,555,180 ) $ 7,236,767 January 1, 2014 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities December 31, 2014 Series D Preferred Stock Purchase Warrants $ 344,570 $ - $ 145,710 $ (330,405 ) $ 159,875 Conversion Option Liabilities 356,197 898,684 (344,202 ) (320,338 ) 590,341 Total Derivatives $ 700,767 $ 898,684 $ (198,492 ) $ (650,743 ) $ 750,216 The issuance fair value for 2015 includes the “day 1” derivative loss on the conversion option derivative liabilities of $805,476 which are included in “change in fair value of derivative liabilities” in the consolidated statement of operations. The fair value of the derivative liabilities were determined using a binomial pricing model. The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2014 Warrants revalued at December 31, 2015 Expected life (in months) 60.0 22.0 11.0 Expected volatility 104.5 % 116.0 % 104.9 % Risk-free interest rate 0.875 % 0.58 % 0.65 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.15 $ 0.16 There were no warrants issued in 2014 with Convertible Debt. The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt in 2015 reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2015 Expected life (in months) 60.0 55.0-60.0 Expected volatility 118.3-120.1 % 136.3-141.6 % Risk-free interest rate 1.48-1.69 % 1.29-1.76 % Exercise price $ 0.40 $ 0.40 Fair value per warrant $ 0.19-$0.21 $ 0.30 The 2015 assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at December 31, 2015 Expected life (in months) 6-24 0-18 18-24 Expected volatility 104.2-153.8 % 86.9%-142.2 % 112.2-114.7 % Risk-free interest rate 0.05-0.99 % 0.01-0.72 % 1.06 % Exercise price $0.10-$0.35 $0.10-$0.25 $ 0.28 Fair value per conversion option $0.09-$0.28 $0.07-$0.26 $0.14-$0.33 The 2014 assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value Conversion options revalued at December 31, 2014 Expected life (in months) 6-24 1-32 Expected volatility 104.4-206.2 % 77.4-154.1 % Risk-free interest rate 0.05-0.99 % 0.03-.0.88 % Exercise price $0.13-$0.45 $0.14-0.35 Fair value per conversion option $0.15-$0.29 $0.00-$0.19
Recently Issued Accounting Standards	xvii. Recently Issued Accounting Standards In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. ASU 2015-03 does not change the recognition and measurement requirements for debt issuance costs. The Company early-adopted ASU 2015-03 as of the end of its Fiscal 2015, and applied its provisions retrospectively. The adoption of ASU 2015-03 resulted in the reclassification of approximately $888,000 unamortized debt issuance costs related to the Company's Senior Notes (see Note 8) from other non-current assets to long-term debt within its consolidated balance sheets as of December 31, 2015. Other than this reclassification, the adoption of ASU 2015-03 and other new pronouncements that have been issued did not have an impact on the Company's consolidated financial statements.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Inventories	The composition of inventory as of December 31, is as follows: 2015 2014 Raw materials $ 310,367 $ 304,928 Finished goods 778,004 595,624 Inventory reserve (50,000 ) (50,000 ) Total $ 1,038,371 $ 850,552
Summary of Customer Concentration Risk Percentage	The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: 2015 2014 Top Five Customers 38 % 32 % Federal Agencies 23 % 6 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2015 2014 Top Five Customers 93 % 86 % Federal Agencies 1 % 9 %
Summary of Computation of Loss per Share	The following table illustrates our computation of loss per share for the years ended December 31: 2015 2014 Numerator: Net loss $ (7,415,298 ) $ (4,612,540 ) Beneficial conversion feature for preferred stock - (1,495,415 ) Preferred dividends accrued (23,194 ) (143,771 ) Net loss applicable to common shareholders $ (7,438,492 ) $ (6,251,726 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 20,726,205 14,264,753 Loss per common share - basic and diluted $ (0.36 ) $ (0.44 )
Summary of Anti-dilutive Securities Excluded from Computation of Earnings per Share	The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: 2015 2014 Stock options 5,571,250 3,406,250 Convertible debt 19,689,286 5,453,571 Common stock warrants 29,227,664 19,182,201 Convertible preferred stock: Series D Convertible Preferred 750,000 750,000 Series G Convertible Preferred 865,700 865,700 Series H Convertible Preferred 1,000,000 1,000,000 Series H2 Convertible Preferred 2,100,000 2,100,000 Series J Convertible Preferred 3,546,000 3,546,000 Series K Convertible Preferred 11,416,000 11,416,000 74,165,900 47,719,722
Summary of Assumptions for Grants of Stock Options	The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the years ended December 31, 2015 and 2014: Assumptions Non-Employee Board Members CEO, other Officers and Employees Expected life 6.0 (yrs) 6.0 (yrs) Expected volatility 116.32%-141.15 % 116.32%-141.15 % Risk-free interest rate 0.65%-2.54 % 0.65%-2.54 % Forfeiture rate 5.00 % 5.00 % Expected dividend yield 0.0 % 0.0 %
Summary of Stock Based Compensation Expense	The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying Consolidated Statements of Operations for the years ended December 31: 2015 2014 Research and development $ 50,617 $ 30,550 Selling and marketing 32,704 19,792 General and administrative 125,668 50,783 Total stock-based compensation expense $ 208,989 $ 101,125
Schedule of Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets and financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015 and December 31, 2014. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Fair value measurements at December 31, 2015 using: December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 294,522 294,522 - - Total Financial Assets $ 294,522 $ 294,522 $ - $ - December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 173,526 - - $ 173,526 Warrants Issued with Convertible Debt 3,122,450 - - 3,122,450 Conversion Option Derivative Liabilities 3,940,791 - - 3,940,791 Total Derivatives $ 7,236,767 $ - $ - $ 7,236,767 Fair value measurements at December 31, 2014 using: Quoted prices in active Significant other Significant unobservable markets observable inputs inputs December 31, 2014 (Level 1) (Level 2) (Level 3) Series D Preferred Stock Purchase Warrants $159,875 - - $159,875 Conversion Option Liabilities 590,341 - - 590,341 Total Derivatives $750,216 $ - $ - $750,216 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: January 1, 2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities December 31, 2015 Series D Preferred Stock Purchase Warrants $ 159,875 $ - $ 13,651 $ - $ 173,526 Warrants Issued with Convertible Debt - 2,320,021 802,429 - 3,122,450 Conversion Option Derivative Liabilities 590,341 5,305,185 600,445 (2,555,180 ) 3,940,791 Total Derivatives $ 750,216 $ 7,625,206 $ 1,416,525 $ (2,555,180 ) $ 7,236,767 January 1, 2014 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities December 31, 2014 Series D Preferred Stock Purchase Warrants $ 344,570 $ - $ 145,710 $ (330,405 ) $ 159,875 Conversion Option Liabilities 356,197 898,684 (344,202 ) (320,338 ) 590,341 Total Derivatives $ 700,767 $ 898,684 $ (198,492 ) $ (650,743 ) $ 750,216
Schedule of Fair Value Assumptions	The fair value of the derivative liabilities were determined using a binomial pricing model. The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2014 Warrants revalued at December 31, 2015 Expected life (in months) 60.0 22.0 11.0 Expected volatility 104.5 % 116.0 % 104.9 % Risk-free interest rate 0.875 % 0.58 % 0.65 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.15 $ 0.16 There were no warrants issued in 2014 with Convertible Debt. The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt in 2015 reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2015 Expected life (in months) 60.0 55.0-60.0 Expected volatility 118.3-120.1 % 136.3-141.6 % Risk-free interest rate 1.48-1.69 % 1.29-1.76 % Exercise price $ 0.40 $ 0.40 Fair value per warrant $ 0.19-$0.21 $ 0.30 The 2015 assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at December 31, 2015 Expected life (in months) 6-24 0-18 18-24 Expected volatility 104.2-153.8 % 86.9%-142.2 % 112.2-114.7 % Risk-free interest rate 0.05-0.99 % 0.01-0.72 % 1.06 % Exercise price $0.10-$0.35 $0.10-$0.25 $ 0.28 Fair value per conversion option $0.09-$0.28 $0.07-$0.26 $0.14-$0.33 The 2014 assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value Conversion options revalued at December 31, 2014 Expected life (in months) 6-24 1-32 Expected volatility 104.4-206.2 % 77.4-154.1 % Risk-free interest rate 0.05-0.99 % 0.03-.0.88 % Exercise price $0.13-$0.45 $0.14-0.35 Fair value per conversion option $0.15-$0.29 $0.00-$0.19

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment as of December 31, 2015 and 2014 consisted of the following components: December 31, 2015 2014 Laboratory and manufacturing equipment $ 226,081 $ 226,081 Office equipment 158,872 149,459 Leasehold improvements 8,117 8,117 PCT collaboration, demonstration and leased systems 461,858 461,858 Total property and equipment 854,928 845,515 Less accumulated depreciation (834,779 ) (809,490 ) Net book value $ 20,149 $ 36,025

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets at December 31, 2015 and 2014 consisted of the following: 2015 2014 PCT Patents $ 778,156 $ 778,156 Less accumulated amortization (778,156 ) (778,156 ) Net book value $ - $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Deferred Tax Liabilities	Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2015 and December 31, 2014 are as follows: 2015 2014 Current deferred taxes Inventories $ 19,640 $ 19,640 Other accruals 23,714 21,818 Less: valuation allowance (43,354 ) (41,458 ) Total current deferred tax assets $ - $ - Long term deferred taxes: Accelerated tax depreciation $ 14,134 $ 12,162 Non-cash, stock-based compensation, nonqualified 562,426 440,614 Goodwill and intangibles - - Operating loss carry forwards and tax credits 12,028,900 9,720,260 Less: valuation allowance (12,605,460 ) (10,173,036 ) Total long term deferred tax assets (liabilities), net - - Total net deferred tax liabilities $ - $ -
Schedule of Effective Income Tax (Benefit) Provision Rate	Our effective income tax (benefit) provision rate was different than the statutory federal income tax (benefit) provision rate as follows for the years ended December 31: 2015 2014 Federal tax provision rate 34 % 34 % Permanent differences (12 )% (2 )% State tax expense 0 % 0 % Refundable AMT and R&D tax credit 0 % 0 % Net operating loss carry back 0 % 0 % Valuation allowance (23 )% (32 )% Effective income tax provision 0 % 0 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2015: 2016 $ 122,220 Thereafter 64,620 Total minimum payments required $ 186,840

Convertible Debt and Other De25

Convertible Debt and Other Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	The specific terms of the $5.4 million PIPE convertible debentures and outstanding balances as of December 31, 2015 are listed in the tables below. Fixed Rate Convertible Notes Inception Date Term Loan Amount Outstanding Balance Original Issue Discount Interest Rate Deferred Finance Fees Discount related to Fair value of conversion feature and warrants Prepayment Penalty July 22, 2015 24 months $ 2,180,000 $ 2,180,000 $ 218,000 1 10 % $ 388,532 $ 2,163,074 20 % September 25, 2015 24 months 1,100,000 1,100,000 110,000 1 10 % 2 185,956 1,022,052 20 % October 2, 2015 24 months 150,000 150,000 15,000 1 10 % 2 26,345 140,832 20 % October 6, 2015 24 months 30,000 30,000 3,000 1 10 % 2 5,168 26,721 20 % October 14, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,954 49,377 20 % November 2, 2015 24 months 250,000 250,000 25,000 1 10 % 2 43,079 222,723 20 % November 10, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,790 46,984 20 % November 12, 2015 24 months 215,000 215,000 21,500 1 10 % 2 38,518 212,399 20 % November 20, 2015 24 months 200,000 200,000 20,000 1 10 % 2 37,185 200,000 20 % December 4, 2015 24 months 170,000 170,000 17,000 1 10 % 2 37,352 170,000 20 % December 11, 2015 24 months 360,000 360,000 36,000 1 10 % 2 75,449 360,000 20 % December 18, 2015 24 months 55,000 55,000 5,500 1 10 % 2 11,714 55,000 20 % December 31, 2015 24 months 100,000 100,000 10,000 1 10 % 2 20,634 100,000 20 % $ 4,910,000 $ 4,910,000 $ 491,000 $ 887,676 $ 4,769,162 1 The original issue discount is reflected in the first year. 2 The annual interest starts accruing in the second year. As of December 31, 2015, the Company also had an outstanding convertible note with a third party amounting to $100,000. The note is convertible at a fixed rate of $0.25 and matures in July 2016. Variable Rate Convertible Notes Inception Date Term Loan Amount Interest Rate Fees Fair value of conversion feature Prepayment Penalty Discount to VWAP Share reserve requirement December 4, 2013 12 months $ 223,000 * 4 % $ 10,000 $ 59,903 20 % - February 2, 2015 12 months 100,000 * 4 % 5,000 62,219 19-33 % - February 2, 2015 12 months 120,000 * 4 % 5,000 74,663 19-33 % - February 22, 2015 six months 100,000 * 4 % - 61,597 19-33 % - February 25, 2015 12 months 112,500 * 8 % 4,000 312,847 19-33 % - March 4, 2015 12 months 52,500 * 4 % 2,500 53,213 19-38 % - March 6, 2015 12 months 236,250 * 2 % 33,900 212,918 19-35 % - March 17, 2015 24 months 50,000 * 4 % - 64,382 19-33 % - March 20, 2015 12 months 25,000 * 4 % - 25,077 19-33 % - March 26, 2015 12 months 150,000 * 6 % 2,000 164,501 19-37.5 % - March 27, 2015 12 months 52,500 * 4 % 2,500 57,502 19-38 % - March 27, 2015 12 months 100,000 * 8 % 8,000 154,359 19-38 % - April 1, 2015 12 months 100,000 * 8 % - 155,793 25-35 % 40% of 10 days - April 20, 2015 12 months 81,250 * 4 % 6,563 117,679 20 % - April 28, 2015 12 months 54,050 * 9 % 4,050 35,143 20 % - May 12, 2015 12 months 107,764 * 4 % 7,763 145,527 20 % - May 20, 2015 12 months 100,000 * 4 % - 92,715 9.5-33 % 45% of 10 days 3,000,000 May 26, 2015 12 months 60,000 * 8 % 3,500 79,287 10-35 % - June 23, 2015 12 months 126,000 * 4 % 6,000 108,297 19-33 % 35% of 15 days 3,101,000 June 24, 2015 24 months 50,000 * 4 % - 54,511 19-33 % 35% of 10 days 1,000,000 July 2, 2015 12 months 52,500 * 4 % 2,500 54,297 19-33 % 35% of 15 days 1,500,000 July 2, 2015 12 months 52,500 * 4 % 2,500 54,297 19-33 % 35% of 15 days 1,000,000 $ 2,105,814 $ 105,776 $ 2,200,727 9,601,000 * The loans above either had outstanding balances as of December 31, 2014 or were issued in 2015 and subsequently paid off in 2015.
Summary of Changes in Convertible Debt, Net of Unamortized Discount	The following table provides a summary of the changes in convertible debt, net of unamortized discount, during 2015: 2015 Balance at January 1, $ 1,004,513 Issuance of convertible debt, face value 7,287,317 Original issue discount (567,780 ) Debt discount from derivative liabilities (embedded conversion option and warrants) (6,433,054 ) Deferred financing fees (887,676 ) Repayment of convertible debt (2,653,990 ) Conversion of convertible debt into common stock (382,054 ) Fees added to principal debt 84,000 Settlement of prepayment penalty (96,023 ) Amortization of debt discount to interest expense through December 31, 2,922,089 Balance at December 31, 277,342 Less: current portion 100,000 Convertible debt, long-term portion $ 177,342

Stockholders' (Deficit) (Tables

Stockholders' (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Schedule of Assumption Used	In connection with the Series K Warrants, we calculated the fair value of the warrants received as described above using the Black- Scholes formula with the below assumptions: Assumptions Series K Series K Series K Series K Series K Contractual life (in months) 36 36 36 36 36 Expected volatility 136.1 152.4 152.7 153.9 153.9 Risk-free interest rate 0.39 % 0.39 % 0.39 % 0.90 % 0.90 % Exercise price $ 0.3125 $ 0.3125 $ 0.425 $ 0.375 $ 0.3125 Fair value per warrant $ 0.20 $ 0.30 $ 0.37 $ 0.29 $ 0.23
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following tables summarize information concerning options and warrants outstanding and exercisable: Stock Options Warrants Total Shares Weighted Average price per share Shares Weighted Average price per share Shares Exercisable Balance outstanding, January 1, 2014 1,771,708 $ 0.71 15,012,327 $ 0.57 16,784,035 16,611,528 Granted 1,675,500 0.30 8,903,000 0.38 10,578,500 Exercised - - (4,208,658 ) 0.25 (4,208,658 ) Expired (10,000 ) 1.00 (524,468 ) 0.74 (534,468 ) Forfeited (30,958 ) 0.71 - - (30,958 ) Balance outstanding, December 31, 2014 3,406,250 $ 0.51 19,182,201 $ 0.49 22,588,451 20,858,111 Granted 2,500,000 0.40 10,837,141 0.40 13,401,426 Exercised - - - - - Expired (205,000 ) 1.00 (791,678 ) 0.31 (996,678 ) Forfeited (130,000 ) 0.70 - - (130,000 ) Balance outstanding, December 31, 2015 5,571,250 $ 0.44 29,227,664 $ 0.44 34,863,199 31,664,469
Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range	The weighted average fair value of options issued on their grant dates was $0.27 for the year ended December 31, 2015. Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Exercise Prices Number of Options Remaining Contractual Life (Years) Exercise Price Number of Options Remaining Contractual Life (Years) Exercise Price $0.30 - $0.39 1,675,500 8.7 $ 0.30 986,612 8.7 $ 0.30 0.40 - 0.49 2,811,000 9.7 0.40 311,000 7.4 0.40 0.50 - 0.59 226,250 6.6 0.50 226,250 6.6 0.50 0.60 - 0.69 402,500 4.1 0.60 392,658 4.1 0.60 0.70 - 1.25 456,000 2.1 1.00 456,000 2.1 1.00 $0.30 - $1.25 5,571,250 8.3 $ 0.44 2,372,520 6.3 $ 0.52

Business Overview (Details Narr

Business Overview (Details Narrative)	12 Months Ended
	Dec. 31, 2015lb
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Pounds per square inch	35,000

Going Concern (Details Narrativ

Going Concern (Details Narrative)	12 Months Ended
	Dec. 31, 2015USD ($)
Going Concern
Net proceeds from additional convertible and non-convertible debt	$ 6,822,255

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Intangible assets amortization of straight line period	16 years
Intangible assets	$ 0	$ 0
Forfeiture rate percentage	5.00%
Stock-based compensation expense	$ 208,989	101,125
Fair value of stock options awarded	598,582	$ 401,617
Fair value of unvested stock options amortized	740,117
Advertising costs	12,291
Derivative liabilities	805,476
Reclassification of unamortized debt issuance costs	888,000
2016 [Member]
Non-cash stock based compensation expense	342,000
2017 [Member]
Non-cash stock based compensation expense	198,680
2018 [Member]
Non-cash stock based compensation expense	$ 199,437
Everest [Member]
Number of common stock exchanged during period	1,000,000
Exchanged shaers form investments holdings	601,500
Fair value of investment	$ 294,522
Preice per share	$ 0.49
Laboratory Equipment [Member]
Property and equipment estimated useful life	3 years
Management Information Systems And Office Equipment [Member] | Minimum [Member]
Property and equipment estimated useful life	3 years
Management Information Systems And Office Equipment [Member] | Maximum [Member]
Property and equipment estimated useful life	5 years
PCT Collaboration, Demonstration and Leased Systems [Member]
Property and equipment estimated useful life	3 years

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Raw materials	$ 310,367	$ 304,928
Finished goods	778,004	595,624
Inventory reserve	(50,000)	(50,000)
Total Inventories	$ 1,038,371	$ 850,552

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Summary of Customer Concentration Risk Percentage (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Top Five Customers [Member] | Revenue [Member]
Concentration as a percentage	38.00%	32.00%
Top Five Customers [Member] | Accounts Receivable [Member]
Concentration as a percentage	93.00%	86.00%
Federal Agencies [Member] | Revenue [Member]
Concentration as a percentage	23.00%	6.00%
Federal Agencies [Member] | Accounts Receivable [Member]
Concentration as a percentage	1.00%	9.00%

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Summary of Computation of Loss per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Net loss	$ (7,415,298)	$ (4,612,540)
Beneficial conversion feature for preferred stock		(1,495,415)
Preferred dividends accrued	$ (23,194)	(143,771)
Net loss applicable to common shareholders	$ (7,438,492)	$ (6,251,726)
Weighted average common stock shares outstanding	20,726,205	14,264,753
Loss per common share - basic and diluted	$ (0.36)	$ (0.44)

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Summary of Anti-dilutive Securities Excluded from Computation of Earnings per Share (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Total potentially dilutive shares	74,165,900	47,719,722
Stock Options [Member]
Total potentially dilutive shares	5,571,250	3,406,250
Convertible Debt [Member]
Total potentially dilutive shares	19,689,286	5,453,571
Common Stock Warrants [Member]
Total potentially dilutive shares	29,227,664	19,182,201
Series D Convertible Preferred Stock [Member]
Total potentially dilutive shares	750,000	750,000
Series G Convertible Preferred Stock [Member]
Total potentially dilutive shares	865,700	865,700
Series H Convertible Preferred Stock [Member]
Total potentially dilutive shares	1,000,000	1,000,000
Series H2 Convertible Preferred Stock [Member]
Total potentially dilutive shares	2,100,000	2,100,000
Series J Convertible Preferred Stock [Member]
Total potentially dilutive shares	3,546,000	3,546,000
Series K Convertible Preferred Stock [Member]
Total potentially dilutive shares	11,416,000	11,416,000

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Summary of Assumptions for Grants of Stock Options (Details)	12 Months Ended
	Dec. 31, 2015
Forfeiture rate	5.00%
Non-Employee Board Members [Member]
Expected life	6 years
Expected volatility Minimum	116.32%
Expected volatility Maximum	141.15%
Risk-free interest rate Minimum	0.65%
Risk-free interest rate Maximum	2.54%
Forfeiture rate	5.00%
Expected dividend yield	0.00%
CEO, other Officers and Employees [Member]
Expected life	6 years
Expected volatility Minimum	116.32%
Expected volatility Maximum	141.15%
Risk-free interest rate Minimum	0.65%
Risk-free interest rate Maximum	2.54%
Forfeiture rate	5.00%
Expected dividend yield	0.00%

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Summary of Stock Based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Stock-based compensation expense	$ 208,989	$ 101,125
Research and Development [Member]
Stock-based compensation expense	50,617	30,550
Selling and Marketing [Member]
Stock-based compensation expense	32,704	19,792
General and Administrative [Member]
Stock-based compensation expense	$ 125,668	$ 50,783

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Schedule of Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair value of derivative liability	$ 7,236,767
Balance	750,216	$ 700,767
Issuance fair value	7,625,206	898,684
Change in Fair Value	1,416,525	(198,492)
Gain on extinguishment of derivative liabilities	(2,555,180)	(650,743)
Balance	7,236,767	750,216
Quoted Prices in Active Markets [Member]
Fair value of derivative liability	$ 294,522
Significant Other Observable Inputs [Member]
Fair value of derivative liability
Significant Unobservable Inputs [Member]
Fair value of derivative liability	$ 7,236,767
Available-For-Sale Equity Securities [Member]
Total Financial Assets	294,522
Available-For-Sale Equity Securities [Member] | Quoted Prices in Active Markets [Member]
Total Financial Assets	$ 294,522
Available-For-Sale Equity Securities [Member] | Significant Other Observable Inputs [Member]
Total Financial Assets
Available-For-Sale Equity Securities [Member] | Significant Unobservable Inputs [Member]
Total Financial Assets
Series D Preferred Stock Purchase Warrants [Member]
Fair value of derivative liability	$ 173,526
Balance	$ 159,875	$ 344,570
Issuance fair value
Change in Fair Value	$ 13,651	$ 145,710
Gain on extinguishment of derivative liabilities		(330,405)
Balance	$ 173,526	$ 159,875
Series D Preferred Stock Purchase Warrants [Member] | Quoted Prices in Active Markets [Member]
Fair value of derivative liability
Series D Preferred Stock Purchase Warrants [Member] | Significant Other Observable Inputs [Member]
Fair value of derivative liability
Series D Preferred Stock Purchase Warrants [Member] | Significant Unobservable Inputs [Member]
Fair value of derivative liability	$ 173,526
Warrants Issued with Convertible Debt [Member]
Fair value of derivative liability	$ 3,122,450
Balance
Issuance fair value	$ 2,320,021
Change in Fair Value	$ 802,429
Gain on extinguishment of derivative liabilities
Balance	$ 3,122,450
Warrants Issued with Convertible Debt [Member] | Quoted Prices in Active Markets [Member]
Fair value of derivative liability
Warrants Issued with Convertible Debt [Member] | Significant Other Observable Inputs [Member]
Fair value of derivative liability
Warrants Issued with Convertible Debt [Member] | Significant Unobservable Inputs [Member]
Fair value of derivative liability	$ 3,122,450
Conversion Option Derivative Liabilities [Member]
Fair value of derivative liability	3,940,791
Balance	590,341	$ 356,197
Issuance fair value	5,305,185	898,684
Change in Fair Value	600,445	(344,202)
Gain on extinguishment of derivative liabilities	(2,555,180)	(320,338)
Balance	$ 3,940,791	$ 590,341
Conversion Option Derivative Liabilities [Member] | Quoted Prices in Active Markets [Member]
Fair value of derivative liability
Conversion Option Derivative Liabilities [Member] | Significant Other Observable Inputs [Member]
Fair value of derivative liability
Conversion Option Derivative Liabilities [Member] | Significant Unobservable Inputs [Member]
Fair value of derivative liability	$ 3,940,791

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Schedule of Fair Value Assumptions (Details) - $ / shares	Nov. 10, 2011	Dec. 31, 2015	Dec. 31, 2014
Expected life (in months)	60 months
Expected volatility	104.50%
Risk-free interest rate	0.875%
Exercise price	$ 0.81
Fair value per share	$ 0.54
Warrants Revalued at December 31, 2014 [Member]
Expected life (in months)			22 months
Expected volatility			116.00%
Risk-free interest rate			0.58%
Exercise price			$ 0.25
Fair value per share			$ 0.15
Warrants Revalued at December 31, 2015 [Member]
Expected life (in months)		11 months
Expected volatility		104.90%
Risk-free interest rate		0.65%
Exercise price		$ .25
Fair value per share		0.16
Warrants Revalued at December 31, 2015 [Member] | Warrants Issued with Convertible Debt [Member]
Exercise price		0.40
Fair value per share		$ 0.30
Warrants Revalued at December 31, 2015 [Member] | Warrants Issued with Convertible Debt [Member] | Minimum [Member]
Expected life (in months)		55 months
Expected volatility		136.30%
Risk-free interest rate		1.29%
Warrants Revalued at December 31, 2015 [Member] | Warrants Issued with Convertible Debt [Member] | Maximum [Member]
Expected life (in months)		60 months
Expected volatility		141.60%
Risk-free interest rate		1.76%
Issuance Fair Value [Member] | Minimum [Member]
Expected life (in months)		6 months	6 months
Expected volatility		104.20%	104.40%
Risk-free interest rate		0.05%	0.05%
Exercise price		$ .10	$ 0.13
Fair value per share		$ 0.09	$ 0.15
Issuance Fair Value [Member] | Maximum [Member]
Expected life (in months)		24 months	24 months
Expected volatility		153.80%	206.20%
Risk-free interest rate		0.99%	0.99%
Exercise price		$ .35	$ 0.45
Fair value per share		$ 0.28	$ 0.29
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member]
Expected life (in months)		60 months
Exercise price		$ .40
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member] | Minimum [Member]
Expected volatility		118.30%
Risk-free interest rate		1.48%
Fair value per share		$ 0.19
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member] | Maximum [Member]
Expected volatility		120.10%
Risk-free interest rate		1.69%
Fair value per share		$ 0.21
Settlement Fair Value [Member] | Minimum [Member]
Expected life (in months)		0 years
Expected volatility		86.90%
Risk-free interest rate		0.01%
Exercise price		$ 0.10
Fair value per share		$ 0.07
Settlement Fair Value [Member] | Maximum [Member]
Expected life (in months)		18 months
Expected volatility		142.20%
Risk-free interest rate		0.072%
Exercise price		$ 0.25
Fair value per share		$ 0.26
Conversion options revalued at December 31, 2015 [Member]
Risk-free interest rate		1.06%
Exercise price		$ 0.28
Conversion options revalued at December 31, 2015 [Member] | Minimum [Member]
Expected life (in months)		18 months
Expected volatility		112.20%
Fair value per share		$ 0.14
Conversion options revalued at December 31, 2015 [Member] | Maximum [Member]
Expected life (in months)		24 months
Expected volatility		114.70%
Fair value per share		$ 0.33
Conversion options revalued at December 31, 2014 [Member] | Minimum [Member]
Expected life (in months)			1 month
Expected volatility			77.40%
Risk-free interest rate			0.03%
Exercise price			$ 0.14
Fair value per share			$ 0
Conversion options revalued at December 31, 2014 [Member] | Maximum [Member]
Expected life (in months)			32 months
Expected volatility			154.10%
Risk-free interest rate			0.88%
Exercise price			$ 0.35
Fair value per share			$ 0.19

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property And Equipment Net Details Narrative
Depreciation expense	$ 25,288	$ 29,213

Property and Equipment, net - S

Property and Equipment, net - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property And Equipment Net - Schedule Of Property And Equipment Details
Laboratory and manufacturing equipment	$ 226,081	$ 226,081
Office equipment	158,872	149,459
Leasehold improvements	8,117	8,117
PCT collaboration, demonstration and leased systems	461,858	461,858
Total property and equipment	854,928	845,515
Less accumulated depreciation	(834,779)	(809,490)
Net book value	$ 20,149	$ 36,025

Intangible Assets, Net (Details

Intangible Assets, Net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Amortization expense		$ 36,498
PCT Patents [Member]
Amortized to expense on a straight line basis at rate per year	$ 48,632
Estimated remaining useful lives of approximately	6 years

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Intangible Assets Net - Schedule Of Intangible Assets Details
PCT Patents	$ 778,156	$ 778,156
Less accumulated amortization	$ (778,156)	$ (778,156)
Net book value

Retirement Plan (Details Narrat

Retirement Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Company-matching contributions	$ 22,098	$ 10,022

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Research and development tax credit carryforwards	$ 14,134	$ 14,134	$ 12,162
Federal Income Tax [Member]
Operating loss carry-forwards	$ 26,752,000	26,752,000
Operating loss carry-fowards expire term	2018 through 2036
Federal alternative minimum tax credit carryforwards for federal income tax	$ 217,000	$ 217,000
Federal Income Tax [Member] | Research and Development Tax Credit Carryforward [Member]
Operating loss carry-fowards expire term		2016 through 2036
Research and development tax credit carryforwards	1,019,000	$ 1,019,000
State Income Tax [Member]
Operating loss carry-forwards	$ 20,895,000	$ 20,895,000
Operating loss carry-fowards expire term	2016 through 2036
State Income Tax [Member] | Research and Development Tax Credit Carryforward [Member]
Operating loss carry-fowards expire term		2023 through 2031
Research and development tax credit carryforwards	$ 165,000	$ 165,000

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Taxes - Schedule Of Deferred Tax Assets And Deferred Tax Liabilities Details
Current deferred taxes, Inventories	$ 19,640	$ 19,640
Current deferred taxes, Other accruals	23,714	21,818
Current deferred taxes, Less: valuation allowance	$ (43,354)	$ (41,458)
Current deferred taxes, Total current deferred tax assets
Long term deferred taxes, Accelerated tax depreciation	$ 14,134	$ 12,162
Long term deferred taxes, Non-cash, stock-based compensation, nonqualified	$ 562,426	$ 440,614
Long term deferred taxes, Goodwill and intangibles
Long term deferred taxes, Operating loss carry forwards and tax credits	$ 12,028,900	$ 9,720,260
Long term deferred taxes, Less: valuation allowance	$ (12,605,460)	$ (10,173,036)
Long term deferred taxes, Total long term deferred tax assets (liabilities), net
Long term deferred taxes, Total net deferred tax liabilities

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax (Benefit) Provision Rate (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes - Schedule Of Deferred Tax Assets And Deferred Tax Liabilities Details
Federal tax provision rate	34.00%	34.00%
Permanent differences	(12.00%)	(2.00%)
State tax expense	0.00%	0.00%
Refundable AMT and R&D tax credit	0.00%	0.00%
Net operating loss carry back	0.00%	0.00%
Valuation allowance	(23.00%)	(32.00%)
Effective income tax provision	0.00%	0.00%

Commitments and Contingencies46

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2008	Dec. 31, 2015	Dec. 31, 2014
BioMolecular Assays, Inc [Member]
Percentage of royalty on sales of products		5.00%
Royalties		$ 31,301	$ 31,835
Percentage of royalty equal of license or other fees and royalties		20.00%
Battelle Memorial Institute [Member]
Non-refundable initial fee	$ 35,000
Minimum annual royalty		$ 1,200	2,900
Target Discovery Inc [Member]
Minimum annual royalty		22,000	$ 0
November 1, 2015 [Member]
Rental expenses		$ 5,385
Extended lease term		Dec. 31, 2017
Corporate Office [Member]
Rental expenses		$ 4,800
Extended lease term		Dec. 31, 2016

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 122,220
Thereafter	64,620
Total minimum payments required	$ 186,840

Convertible Debt and Other De48

Convertible Debt and Other Debt (Details Narrative) - USD ($)	Aug. 28, 2015	Jul. 21, 2015	May. 29, 2015	Mar. 17, 2015	Jan. 29, 2015	Jan. 15, 2015	Jun. 06, 2014	Dec. 31, 2015	Dec. 31, 2014	Apr. 10, 2015	Mar. 29, 2015	Feb. 25, 2015	Jan. 06, 2014
Gross proceeds from convertible debt								$ 5,558,537	$ 1,126,744
Debenture fee			$ 8,000			$ 13,000				$ 10,000		$ 13,000
Received from related parties								6,300
Payments of advances								12,300	$ 6,394
Convertible Debt [Member]
Proceeds form issuance of private placement								$ 5,000,000
Issuance of warrants to purchase of common stock shares								8,767,857
Warrant exercise price per share								$ 0.40
Fair value of warrant								$ 1,933,375
Gross proceeds from convertible debt								4,910,000
PIPE Convertible Debentures [Member]
Proceeds form issuance of private placement		$ 5,000,000						$ 5,000,000
Other Notes [Member] | Merchant Agreement [Member]
Received in exchange for rights to all customer receipts	$ 300,000			$ 50,000	$ 200,000	150,000					$ 100,000		$ 150,000
Lender paid	384,000		132,000	67,450	278,000	187,500	$ 190,499
Collected rate business day	2,560		$ 1,098	559	1,985	744	$ 756
Proceeds from outstanding balance of previous loan from lender	131,710					67,925
Debenture fee	$ 6,000			$ 999	$ 999	$ 1,875					$ 3,999		$ 3,750
Minimum [Member]
Convertible debentures term								12 months
Percentage of annual interest rates								4.00%
Percentage of pre-payment penalties								19.00%
Maximum [Member]
Convertible debentures term								24 months
Percentage of annual interest rates								10.00%
Percentage of pre-payment penalties								38.00%
Investor [Member]
Convertible debentures term								390 days
Received from related parties								$ 600,000
Non-related Parties [Member] | Non-convertible Debt [Member]
Payments on non-convertible debt from non-related parties								587,949
Certain Officers [Member]
Received from related parties								6,300
Payments of advances								$ 12,300

Convertible Debt and Other De49

Convertible Debt and Other Debt - Schedule of Convertible Debts and Outstanding Balances (Details) - USD ($)		12 Months Ended
		Dec. 31, 2015	May. 29, 2015	May. 12, 2015	Apr. 10, 2015	Feb. 25, 2015	Jan. 15, 2015	Nov. 11, 2014	Jun. 04, 2014	Dec. 04, 2013
Outstanding Balance								$ 75,000	$ 150,000	$ 223,000
Deferred Finance Fees			$ 8,000		$ 10,000	$ 13,000	$ 13,000
Minimum [Member]
Interest Rate		4.00%
Maximum [Member]
Interest Rate		10.00%
Fixed Rate Convertible Notes [Member]
Loan Amount		$ 4,910,000
Outstanding Balance		4,910,000
Original Issue Discount		491,000
Deferred Finance Fees		887,676
Discount related to Fair value of conversion feature and warrants		$ 4,769,162
Fixed Rate Convertible Notes [Member] | Convertible Debt [Member]
Inception Date		Jul. 22, 2015
Term		24 months
Loan Amount		$ 2,180,000
Outstanding Balance		2,180,000
Original Issue Discount	[1]	$ 218,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 388,532
Discount related to Fair value of conversion feature and warrants		$ 2,163,074
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Two [Member]
Inception Date		Sep. 25, 2015
Term		24 months
Loan Amount		$ 1,100,000
Outstanding Balance		1,100,000
Original Issue Discount	[1]	$ 110,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 185,956
Discount related to Fair value of conversion feature and warrants		$ 1,022,052
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Three [Member]
Inception Date		Oct. 2, 2015
Term		24 months
Loan Amount		$ 150,000
Outstanding Balance		150,000
Original Issue Discount	[1]	$ 15,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 26,345
Discount related to Fair value of conversion feature and warrants		$ 140,832
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Four [Member]
Inception Date		Oct. 6, 2015
Term		24 months
Loan Amount		$ 30,000
Outstanding Balance		30,000
Original Issue Discount	[1]	$ 3,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 5,168
Discount related to Fair value of conversion feature and warrants		$ 26,721
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Five [Member]
Inception Date		Oct. 14, 2015
Term		24 months
Loan Amount		$ 50,000
Outstanding Balance		50,000
Original Issue Discount	[1]	$ 5,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 8,954
Discount related to Fair value of conversion feature and warrants		$ 49,377
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Six [Member]
Inception Date		Nov. 2, 2015
Term		24 months
Loan Amount		$ 250,000
Outstanding Balance		250,000
Original Issue Discount	[1]	$ 25,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 43,079
Discount related to Fair value of conversion feature and warrants		$ 222,723
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Seven [Member]
Inception Date		Nov. 10, 2015
Term		24 months
Loan Amount		$ 50,000
Outstanding Balance		50,000
Original Issue Discount	[1]	$ 5,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 8,790
Discount related to Fair value of conversion feature and warrants		$ 46,984
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Eight [Member]
Inception Date		Nov. 12, 2015
Term		24 months
Loan Amount		$ 215,000
Outstanding Balance		215,000
Original Issue Discount	[1]	$ 21,500
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 38,518
Discount related to Fair value of conversion feature and warrants		$ 212,399
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Nine [Member]
Inception Date		Nov. 20, 2015
Term		24 months
Loan Amount		$ 200,000
Outstanding Balance		200,000
Original Issue Discount	[1]	$ 20,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 37,185
Discount related to Fair value of conversion feature and warrants		$ 200,000
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Ten [Member]
Inception Date		Dec. 4, 2015
Term		24 months
Loan Amount		$ 170,000
Outstanding Balance		170,000
Original Issue Discount	[1]	$ 17,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 37,352
Discount related to Fair value of conversion feature and warrants		$ 170,000
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Eleven [Member]
Inception Date		Dec. 11, 2015
Term		24 months
Loan Amount		$ 360,000
Outstanding Balance		360,000
Original Issue Discount	[1]	$ 36,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 75,449
Discount related to Fair value of conversion feature and warrants		$ 360,000
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Tweleve [Member]
Inception Date		Dec. 18, 2015
Term		24 months
Loan Amount				$ 55,000
Outstanding Balance				$ 55,000
Original Issue Discount	[1]	$ 5,500
Interest Rate	[2]			10.00%
Deferred Finance Fees				$ 11,714
Discount related to Fair value of conversion feature and warrants		$ 55,000
Prepayment Penalty		20.00%
Fixed Rate Convertible Notes [Member] | Convertible Debt Thirteen [Member]
Inception Date		Dec. 31, 2015
Term		24 months
Loan Amount		$ 100,000
Outstanding Balance		100,000
Original Issue Discount	[1]	$ 10,000
Interest Rate	[2]	10.00%
Deferred Finance Fees		$ 20,634
Discount related to Fair value of conversion feature and warrants		$ 100,000
Prepayment Penalty		20.00%
Variable Rate Convertible Notes [Member]
Loan Amount		$ 2,105,814
Deferred Finance Fees		105,776
Discount related to Fair value of conversion feature and warrants		$ 2,200,727
Share reserve requirement		9,601,000
Variable Rate Convertible Notes [Member] | Convertible Debt [Member]
Inception Date		Dec. 4, 2013
Term		12 months
Loan Amount	[3]	$ 223,000
Interest Rate		4.00%
Deferred Finance Fees		$ 10,000
Discount related to Fair value of conversion feature and warrants		$ 59,903
Prepayment Penalty		20.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Two [Member]
Inception Date		Feb. 2, 2015
Term		12 months
Loan Amount	[3]	$ 100,000
Interest Rate		4.00%
Deferred Finance Fees		$ 5,000
Discount related to Fair value of conversion feature and warrants		$ 62,219
Variable Rate Convertible Notes [Member] | Convertible Debt Two [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Two [Member] | Maximum [Member]
Prepayment Penalty		33.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Three [Member]
Inception Date		Feb. 2, 2015
Term		12 months
Loan Amount	[3]	$ 120,000
Interest Rate		4.00%
Deferred Finance Fees		$ 5,000
Discount related to Fair value of conversion feature and warrants		$ 74,663
Variable Rate Convertible Notes [Member] | Convertible Debt Three [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Three [Member] | Maximum [Member]
Prepayment Penalty		33.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Four [Member]
Inception Date		Feb. 22, 2015
Term		6 months
Loan Amount	[3]	$ 100,000
Interest Rate		4.00%
Deferred Finance Fees		$ 0
Discount related to Fair value of conversion feature and warrants		$ 61,597
Variable Rate Convertible Notes [Member] | Convertible Debt Four [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Four [Member] | Maximum [Member]
Prepayment Penalty		33.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Five [Member]
Inception Date		Feb. 25, 2015
Term		12 months
Loan Amount	[3]	$ 112,500
Interest Rate		8.00%
Deferred Finance Fees		$ 4,000
Discount related to Fair value of conversion feature and warrants		$ 312,847
Variable Rate Convertible Notes [Member] | Convertible Debt Five [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Five [Member] | Maximum [Member]
Prepayment Penalty		33.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Six [Member]
Inception Date		Mar. 4, 2015
Term		12 months
Loan Amount	[3]	$ 52,500
Interest Rate		4.00%
Deferred Finance Fees		$ 2,500
Discount related to Fair value of conversion feature and warrants		$ 53,213
Variable Rate Convertible Notes [Member] | Convertible Debt Six [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Six [Member] | Maximum [Member]
Prepayment Penalty		38.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Seven [Member]
Inception Date		Mar. 6, 2015
Term		12 months
Loan Amount	[3]	$ 236,250
Interest Rate		2.00%
Deferred Finance Fees		$ 33,900
Discount related to Fair value of conversion feature and warrants		$ 212,918
Variable Rate Convertible Notes [Member] | Convertible Debt Seven [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Seven [Member] | Maximum [Member]
Prepayment Penalty		35.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Eight [Member]
Inception Date		Mar. 17, 2015
Term		24 months
Loan Amount	[3]	$ 50,000
Interest Rate		4.00%
Deferred Finance Fees		$ 0
Discount related to Fair value of conversion feature and warrants		$ 64,382
Variable Rate Convertible Notes [Member] | Convertible Debt Eight [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Eight [Member] | Maximum [Member]
Prepayment Penalty		33.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Nine [Member]
Inception Date		Mar. 20, 2015
Term		12 months
Loan Amount	[3]	$ 25,000
Interest Rate		4.00%
Deferred Finance Fees		$ 0
Discount related to Fair value of conversion feature and warrants		$ 25,077
Variable Rate Convertible Notes [Member] | Convertible Debt Nine [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Nine [Member] | Maximum [Member]
Prepayment Penalty		33.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Ten [Member]
Inception Date		Mar. 26, 2015
Term		12 months
Loan Amount	[3]	$ 150,000
Interest Rate		6.00%
Deferred Finance Fees		$ 2,000
Discount related to Fair value of conversion feature and warrants		$ 164,501
Variable Rate Convertible Notes [Member] | Convertible Debt Ten [Member] | Minimum [Member]
Prepayment Penalty		37.50%
Variable Rate Convertible Notes [Member] | Convertible Debt Ten [Member] | Maximum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Eleven [Member]
Inception Date		Mar. 27, 2015
Term		12 months
Loan Amount	[3]	$ 52,500
Interest Rate		4.00%
Deferred Finance Fees		$ 2,500
Discount related to Fair value of conversion feature and warrants		$ 57,502
Variable Rate Convertible Notes [Member] | Convertible Debt Eleven [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Eleven [Member] | Maximum [Member]
Prepayment Penalty		38.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Tweleve [Member]
Inception Date		Mar. 27, 2015
Term		12 months
Loan Amount	[3]	$ 100,000
Interest Rate		8.00%
Deferred Finance Fees		$ 8,000
Discount related to Fair value of conversion feature and warrants		$ 154,359
Variable Rate Convertible Notes [Member] | Convertible Debt Tweleve [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Tweleve [Member] | Maximum [Member]
Prepayment Penalty		38.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Thirteen [Member]
Inception Date		Apr. 1, 2015
Term		12 months
Loan Amount	[3]	$ 100,000
Interest Rate		8.00%
Deferred Finance Fees		$ 0
Discount related to Fair value of conversion feature and warrants		$ 155,793
Discount to VWAP		40% of 10 days
Share reserve requirement		3,000,000
Variable Rate Convertible Notes [Member] | Convertible Debt Thirteen [Member] | Minimum [Member]
Prepayment Penalty		25.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Thirteen [Member] | Maximum [Member]
Prepayment Penalty		35.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Fourteen [Member]
Inception Date		Apr. 20, 2015
Term		12 months
Loan Amount	[3]	$ 81,250
Interest Rate		4.00%
Deferred Finance Fees		$ 6,563
Discount related to Fair value of conversion feature and warrants		$ 117,679
Prepayment Penalty		20.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Fifteen [Member]
Inception Date		Apr. 28, 2015
Term		12 months
Loan Amount	[3]	$ 54,050
Interest Rate		9.00%
Deferred Finance Fees		$ 4,050
Discount related to Fair value of conversion feature and warrants		$ 35,143
Prepayment Penalty		20.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Sixteen [Member]
Inception Date		May 12, 2015
Term		12 months
Loan Amount	[3]	$ 107,764
Interest Rate		4.00%
Deferred Finance Fees		$ 7,763
Discount related to Fair value of conversion feature and warrants		$ 145,527
Prepayment Penalty		20.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Seventeen [Member]
Inception Date		May 12, 2015
Term		12 months
Loan Amount	[3]	$ 100,000
Interest Rate		4.00%
Deferred Finance Fees		$ 0
Discount related to Fair value of conversion feature and warrants		$ 92,715
Discount to VWAP		45% of 10 days
Share reserve requirement		3,000,000
Variable Rate Convertible Notes [Member] | Convertible Debt Seventeen [Member] | Minimum [Member]
Prepayment Penalty		33.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Seventeen [Member] | Maximum [Member]
Prepayment Penalty		9.50%
Variable Rate Convertible Notes [Member] | Convertible Debt Eighteen [Member]
Inception Date		May 26, 2015
Term		12 months
Loan Amount	[3]	$ 60,000
Interest Rate		8.00%
Deferred Finance Fees		$ 3,500
Discount related to Fair value of conversion feature and warrants		$ 79,287
Variable Rate Convertible Notes [Member] | Convertible Debt Eighteen [Member] | Minimum [Member]
Prepayment Penalty		35.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Eighteen [Member] | Maximum [Member]
Prepayment Penalty		10500.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Nineteen [Member]
Inception Date		Jun. 23, 2015
Term		12 months
Loan Amount	[3]	$ 126,000
Interest Rate		4.00%
Deferred Finance Fees		$ 6,000
Discount related to Fair value of conversion feature and warrants		$ 108,297
Discount to VWAP		35% of 15 days
Share reserve requirement		3,101,000
Variable Rate Convertible Notes [Member] | Convertible Debt Nineteen [Member] | Minimum [Member]
Prepayment Penalty		33.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Nineteen [Member] | Maximum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Twenty [Member]
Inception Date		Jun. 24, 2015
Term		24 months
Loan Amount	[3]	$ 50,000
Interest Rate		4.00%
Deferred Finance Fees		$ 0
Discount related to Fair value of conversion feature and warrants		$ 54,511
Discount to VWAP		35% of 10 days
Share reserve requirement		1,000,000
Variable Rate Convertible Notes [Member] | Convertible Debt Twenty [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Twenty [Member] | Maximum [Member]
Prepayment Penalty		33.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Twenty One [Member]
Inception Date		Jul. 2, 2015
Term		12 months
Loan Amount	[3]	$ 52,500
Interest Rate		4.00%
Deferred Finance Fees		$ 2,500
Discount related to Fair value of conversion feature and warrants		$ 54,297
Discount to VWAP		35% of 15 days
Share reserve requirement		1,500,000
Variable Rate Convertible Notes [Member] | Convertible Debt Twenty One [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Twenty One [Member] | Maximum [Member]
Prepayment Penalty		33.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Twenty Two [Member]
Inception Date		Jul. 2, 2015
Term		12 months
Loan Amount	[3]	$ 52,500
Interest Rate		4.00%
Deferred Finance Fees		$ 2,500
Discount related to Fair value of conversion feature and warrants		$ 54,297
Discount to VWAP		35% of 15 days
Share reserve requirement		1,500,000
Variable Rate Convertible Notes [Member] | Convertible Debt Twenty Two [Member] | Minimum [Member]
Prepayment Penalty		19.00%
Variable Rate Convertible Notes [Member] | Convertible Debt Twenty Two [Member] | Maximum [Member]
Prepayment Penalty		33.00%
[1]	The original issue discount is reflected in the first year.
[2]	The annual interest starts accruing in the second year.
[3]	The loans above either had outstanding balances as of December 31, 2014 or were issued in 2015 and subsequently paid off in 2015.

Convertible Debt and Other De50

Convertible Debt and Other Debt - Summary of Changes in Convertible Debt, Net of Unamortized Discount (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	May. 29, 2015	Apr. 10, 2015	Feb. 25, 2015	Jan. 15, 2015
Original issued discount	$ 2,989,765	$ 1,310,351
Repayment of convertible debt	(2,653,990)	(303,100)
Fees added to principal debt			$ 8,000	$ 10,000	$ 13,000	$ 13,000
Less: current portion	100,000	$ 1,004,513
Convertible debt, long-term portion	177,342
Convertible Debt, Net [Member]
Balance at December 31, 2014	1,004,513
Issuance of convertible debt, face value	7,287,317
Original issued discount	(567,780)
Debt discount from derivative liabilities (embedded conversion option and warrants)	(6,433,054)
Deferred financing fees	(887,676)
Repayment of convertible debt	$ (2,653,990)
Conversion of convertible debt into common stock	(382,054)
Fees added to principal debt	$ 84,000
Settlement of prepayment penalty	(96,023)
Amortization of debt discount to interest expense through December 31, 2015	2,922,089
Balance at December 31, 2015	277,342	$ 1,004,513
Less: current portion	100,000
Convertible debt, long-term portion	$ 177,342

Stockholders' (Deficit) (Detail

Stockholders' (Deficit) (Details Narrative) - USD ($)	Dec. 12, 2015	Oct. 26, 2015	Sep. 25, 2015	Aug. 14, 2015	Aug. 13, 2015	Jul. 21, 2015	May. 29, 2015	Apr. 17, 2015	Apr. 10, 2015	Mar. 31, 2015	Mar. 18, 2015	Feb. 25, 2015	Feb. 18, 2015	Jan. 12, 2015	Dec. 23, 2014	Dec. 12, 2014	Nov. 11, 2014	Nov. 09, 2014	Jun. 30, 2014	Feb. 28, 2014	Feb. 02, 2014	Jan. 30, 2014	Jan. 28, 2014	May. 20, 2013	Mar. 28, 2013	Feb. 06, 2013	Jan. 04, 2013	Nov. 15, 2012	Jul. 06, 2012	Dec. 31, 2015	Dec. 31, 2013	Apr. 30, 2012	Nov. 30, 2011	Dec. 31, 2015	Dec. 31, 2014	Jan. 15, 2015	Nov. 12, 2014	Sep. 22, 2014	Jun. 04, 2014	Apr. 04, 2014	Jan. 31, 2014	Dec. 21, 2013	Dec. 12, 2013	Dec. 04, 2013	Dec. 28, 2012
Convertible preferred stock, authorized																														1,000,000				1,000,000
Convertible preferred stock, par value																														$ 0.01				$ 0.01
Convertible preferred stock, shares issued																														1,000,000				1,000,000
Convertible preferred stock, shares outstanding																	40,000
Proceeds from convertible preferred stock																																			$ 1,939,360
Common stock, shares outstanding under the plan																														34,863,199	16,784,035			34,863,199	22,588,451
Convertible debt amount																	$ 75,000																						$ 150,000					$ 223,000
Conversion of convertible debt			$ 30,000		$ 40,000	$ 20,000	$ 35,000	$ 30,000	$ 35,000	$ 27,500	$ 22,500	$ 38,000	$ 25,000	$ 25,000																$ 58,919
Conversion of convertible debt, shares			120,000		160,000	80,000	140,000	120,000	140,000	110,000	90,000	140,741	100,000	100,000																235,676
Debenture fee							$ 8,000		$ 10,000			$ 13,000																								$ 13,000
Number of common stock shares issued for services																																		1,755,091
Number of common stock value issued for consulting and investor services																																		$ 457,030	$ 214,192
Number of restricted common stock purchased		200,000
Interest expense																		$ 10,000																4,146,416	1,303,129
Conversion option liability																														$ 3,940,791				3,940,791
Accrued dividends																																		$ (23,194)	$ (143,771)
Everest Investments Holding [Member]
Aggregate number of units sold				601,500
Sale of stock value of shares received				$ 400,000
2005 Equity Incentive [Member]
Common stock reserved for stock option plan																														1,800,000				1,800,000
Common stock, shares outstanding under the plan																														1,395,750				1,395,750
Common stock, shares available for future grant																														344,250				344,250
2013 Equity Incentive Plan [Member]
Common stock reserved for stock option plan																																											3,000,000
Common stock, shares outstanding under the plan																																											2,107,500
Common stock, shares available for future grant																																											892,500
2015 Equity Incentive Plan [Member]
Common stock reserved for stock option plan																														5,000,000				5,000,000
Common stock, shares outstanding under the plan																														2,068,000				2,068,000
Common stock, shares available for future grant																														2,932,000				2,932,000
Weighted average grant date fair value of options issued																																		$ 0.27
Unrecognized compensation cost																																		$ 740,117
Compensation cost reorganization period																																		2 years 5 months 12 days
Restricted Stock Units [Member] | Everest Investments Holding [Member]
Stock issuance price per share				$ 0.50
Number of restricted common stock purchased				1,000,000
CommonStockMember [Member]
Conversion of convertible debt
Conversion of convertible debt, shares
Number of common stock shares issued for services																																		1,755,091	588,830
Number of common stock value issued for consulting and investor services																																		$ 17,551	$ 5,888
Accrued dividends
Series D Warrant [Member]
Warrants exercise price per share																															$ 0.25	$ 0.40
Change in number of warrants																															628,733	530,406
Number of Warrants issued during period																															1,676,608	1,047,875
Increase decrease in warrants value																																		$ 173,526
Series D Warrant [Member] | Merger Or Consolidation [Member]
Percentage of stock acquired																																		50.00%
Series G Warrant [Member]
Warrants exercise price per share																														$ 0.50				$ 0.50
Number of Warrants issued during period																																		1,495,022
Warrants expiration date																																		Jul. 6, 2015
Change in exercise price of warrants																														0.60				$ 0.60
Series J Warrant [Member]
Warrants exercise price per share																														$ 0.40				$ 0.40
Series J Warrant [Member] | Minimum [Member]
Change in number of warrants																																		5,000,000
Series K Warrant [Member]
Proceeds from direct offering																					$ 5,000,000
Warrants exercise price per share																			$ 0.375	$ 0.425																	$ 0.3125				$ 0.3125	$ 0.3125
Warrant Derivative Liability [Member]
Proceeds from direct offering																																		$ 283,725	$ 149,165
Issuance of warrants to purchase of common stock shares																																			596,658
Warrants exercise price per share																																			$ 0.25
Aggregate warrant to lenders to purchase commno stock shares																																		8,767,857
Aggregate warrant to placement agent to purchase common stock shares																																		1,689,286
Warrant expiring term																																		5 years
Incremental value of warrant extension																																		$ 69,627
Warrant expense recorded																																		$ 93,488
Series A Junior Participating Preferred Stock [Member]
Number of stock designated																														20,000				20,000
Series A Junior Participating Preferred Stock [Member] | Shareholders Purchase Rights Plan [Member]
Purchase price per units sold																														$ 45				$ 45
Percentage of stock acquired																																		50.00%
Conversion price per share																														$ 0.001				$ 0.001
Common stock acquires beneficial ownership description																																		Subject to certain limited exceptions, if a person or group acquires beneficial ownership of 15% or more of our outstanding common stock or if a current 15% beneficial owner acquires additional shares of common stock, each holder of a Right (other than the 15% holder whose Rights become void once such holder reaches the 15% threshold) will thereafter have a right to purchase, upon payment of the purchase price of the Right, that number of shares of our common stock which at the time of such transaction will have a market value equal to two times the purchase price of the Right In the event that, at any time after a person or group acquires 15% or more of our common stock, we are acquired in a merger or other business combination transaction or 50% or more of its consolidated assets or earning power are sold, each holder of a Right will thereafter have the right to purchase, upon payment of the purchase price of the Right, that number of shares of common stock of the acquiring company which at the time of such transaction will have a market value of two times the purchase price of the Right.
Beneficial ownership percentage																																		15.00%
Series A Junior Participating Preferred Stock [Member] | Shareholders Purchase Rights Plan [Member] | CommonStockMember [Member]
Percentage of stock acquired																																		15.00%
Series A Convertible Preferred Stock [Member]
Number of stock designated																														313,960				313,960
Series B Convertible Preferred Stock [Member]
Number of stock designated																														279,256				279,256
Series C Convertible Preferred Stock [Member]
Number of stock designated																														88,098				88,098
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																														850				850	850
Convertible preferred stock, par value																														$ 0.01				$ 0.01	$ 0.01
Convertible preferred stock, shares issued																														300				300	300
Number of stock designated																														850				850
Preferred stock shares outstanding																														300				300	300
Aggregate number of units sold																																	843
Purchase price per units sold																																	$ 1,000
Proceeds from direct offering																																	$ 843,000
Convertible preferred stock, shares outstanding																														1,538.46			1,538.46	1,538.46
Issuance of warrants to purchase of common stock shares																																	614
Warrants exercise price per share																																	$ 0.81
Proceeds from convertible preferred stock																																		$ 559,275
Additional paid in capital and accumulated deficit																																		530,140
Adjustment to additional paid in capital related to the beneficial conversion feature																																		530,140
Amount to be paid at any uncertain situation value per share (subject to accrued but unpaid dividends)																														$ 1,000				$ 1,000
Convertible preferred stock, conversion percentage																																		300.00%
Subsequent financing pro-rata basis percentage																																		50.00%
Preferred stock value issued																														$ 3				$ 3	$ 3
Series D Convertible Preferred Stock [Member] | Merger Or Consolidation [Member]
Proceeds from convertible preferred stock																																		$ 50,000
Percentage of stock acquired																																		50.00%
Series D Convertible Preferred Stock [Member] | Series D Warrant [Member]
Fee paid to investment banker																																		$ 67,000
Proceeds from warrants issued																																		$ 283,725
Series E Convertible Preferred Stock [Member]
Number of stock designated																														500				500
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																														240,000				240,000	240,000
Convertible preferred stock, par value																														$ 0.01				$ 0.01	$ 0.01
Convertible preferred stock, shares issued																														86,570				86,570	86,570
Number of stock designated																														240,000				240,000
Preferred stock shares outstanding																														86,570				86,570	86,570
Aggregate number of units sold																												145,320	145,320
Purchase price per units sold																												$ 5	$ 5
Proceeds from direct offering																												$ 726,600	$ 726,600
Convertible preferred stock, shares outstanding																														10				10
Issuance of warrants to purchase of common stock shares																																		5
Warrants exercise price per share																														$ 0.50				$ 0.50
Convertible preferred stock, conversion percentage																																		12.00%
Percentage of shares purchased for investment																																		6.00%
Value of shares invested in private placements																																		$ 726,600
Cash received in private placement																																		31,100
Conversion of outstanding indebtedness and accrued board of directors' fees																														$ 695,500				$ 695,500
Cumulative dividend rate percentage																																		4.00%
Preferred stock value issued																														$ 866				$ 866	$ 866
Stock issuance price per share																														$ 0.75				$ 0.75
Series G Convertible Preferred Stock [Member] | Minimum [Member]
Proceeds from direct offering																																		$ 2,500,000
Value of shares invested in private placements																																		250,000
Preferred stock value issued																														$ 100,000				$ 100,000
Average daily trading volume																																		10,000
Series G Convertible Preferred Stock [Member] | Maximum [Member]
Preferred stock value issued																														$ 250,000				$ 250,000
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																														10,000				10,000	10,000										10,000
Convertible preferred stock, par value																											$ 0.01			$ 0.01				$ 0.01	$ 0.01
Convertible preferred stock, shares issued																														10,000				10,000	10,000
Number of stock designated																														10,000				10,000
Preferred stock shares outstanding																														10,000				10,000	10,000
Purchase price per units sold																											$ 0.8025
Convertible preferred stock, shares outstanding																											1,000,000			10,000				10,000
Issuance of warrants to purchase of common stock shares																											100
Preferred stock value issued																														$ 100				$ 100	$ 100
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																														21				21	21
Convertible preferred stock, par value															$ 0.01															$ 0.01				$ 0.01	$ 0.01
Convertible preferred stock, shares issued															21															21				21	21
Number of stock designated																														21				21
Preferred stock shares outstanding																														21				21	21
Purchase price per units sold															$ 0.25
Convertible preferred stock, shares outstanding															2,100,000															21				21
Issuance of warrants to purchase of common stock shares															100,000
Preferred stock value issued
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																														6,250				6,250	6,250
Convertible preferred stock, par value																														$ 0.01				$ 0.01	$ 0.01
Convertible preferred stock, shares issued																														3,546				3,546	3,546
Number of stock designated																														6,250				6,250
Preferred stock shares outstanding																														3,546				3,546	3,546
Aggregate number of units sold																								5,087	5,087.5	5,087.5
Purchase price per units sold																								$ 400	$ 400	$ 400
Proceeds from direct offering																								$ 2,034,700	$ 2,034,700	$ 2,034,700								$ 2,500,000
Issuance of warrants to purchase of common stock shares																																		1,000
Warrants exercise price per share																														$ 0.40				$ 0.40
Proceeds from warrants issued																																		$ 885,309
Additional paid in capital and accumulated deficit																																		651,182
Adjustment to additional paid in capital related to the beneficial conversion feature																																		$ 651,182
Convertible preferred stock, conversion percentage																																		4.00%
Percentage of stock acquired																																		6.00%
Value of shares invested in private placements																																		$ 2,034,700
Cash received in private placement																																		921,000
Conversion of outstanding indebtedness and accrued board of directors' fees																														$ 1,113,700				1,113,700
Preferred stock value issued																														$ 36				$ 36	$ 36
Stock issuance price per share																														$ 0.80				$ 0.80
Warrants expiration term																																		P3Y
Legal fees																																		$ 24,405
Series J Convertible Preferred Stock [Member] | Minimum [Member]
Value of shares invested in private placements																																		$ 250,000
Stock issuance price per share																														$ 0.80				$ 0.80
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																														15,000				15,000	15,000
Convertible preferred stock, par value																	$ 0.01		$ 0.01	$ 0.01										$ 0.01				$ 0.01	$ 0.01
Convertible preferred stock, shares issued																	1,000		1,000	1,000										11,416				11,416	11,416			64,000
Number of stock designated																														15,000				15,000
Preferred stock shares outstanding																														11,416				11,416	11,416
Aggregate number of units sold	4,000																1,052		734	1,854			4,875
Purchase price per units sold	$ 250																$ 250		$ 300	$ 340			$ 250
Proceeds from direct offering	$ 1,000,000																$ 263,000		$ 220,000	$ 630,360		$ 1,500,000	$ 1,218,750											$ 100,000
Convertible preferred stock, shares outstanding																														11,416				11,416				64
Issuance of warrants to purchase of common stock shares																	500		500	500			500											1,000
Warrants exercise price per share																	$ 0.3125		$ 0.425	$ 0.425										$ 0.3125				$ 0.3125
Proceeds from warrants issued																																		$ 271,422
Additional paid in capital and accumulated deficit																																		351,421
Adjustment to additional paid in capital related to the beneficial conversion feature																																		$ 351,421
Convertible preferred stock, conversion percentage																																		4.00%
Percentage of stock acquired																																		6.00%
Number of Warrants issued during period																																		500
Value of shares invested in private placements																	$ 3,332,110																	$ 1,000,000
Cash received in private placement																	2,511,404																	572,044
Conversion of outstanding indebtedness and accrued board of directors' fees																	$ 820,706													$ 427,956				427,956
Preferred stock value issued																														$ 114				$ 114	$ 114
Stock issuance price per share																														$ 0.80				$ 0.80
Average daily trading volume																																		50,000
Warrants expiration date																	Nov. 12, 2017		Jun. 30, 2017	Feb. 28, 2017			Jan. 29, 2017
Fee incurred with private placement																																		$ 43,334
Increase in subscription amount																				$ 3,500,000			$ 718,750
Accrued dividends	23,194															$ 143,771
Series K Convertible Preferred Stock [Member] | Tranche Two [Member]
Proceeds from direct offering																							$ 1,500,000
Increase in subscription amount																																									$ 1,218,750
Series K Convertible Preferred Stock [Member] | Tranche Third [Member]
Proceeds from direct offering																				1,500,000
Increase in subscription amount																				$ 630,360
Series K Convertible Preferred Stock [Member] | Fourth Tranche [Member]
Proceeds from direct offering																			$ 1,500,000
Increase in subscription amount																			$ 220,000
Series K Convertible Preferred Stock [Member] | Fifth Tranche [Member]
Proceeds from direct offering																	$ 1,500,000
Increase in subscription amount																																					$ 263,000
Series K Convertible Preferred Stock [Member] | Initial Tranche [Member]
Increase in subscription amount																																											$ 1,000,000
Series K Convertible Preferred Stock [Member] | Minimum [Member]
Proceeds from direct offering	$ 2,500,000
Increase in subscription amount																																								$ 4,500,000
Series K Convertible Preferred Stock [Member] | Maximum [Member]
Increase in subscription amount																																								$ 1,000,000

Stockholders_ (Deficit) - Sched

Stockholders’ (Deficit) - Schedule of Assumption Used (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Nov. 10, 2011
Fair value per warrant		$ 0.54
Series J Warrants February 6, 2013 [Member]
Contractual life (in months)	36 months
Expected volatility	141.80%
Risk-free interest rate	0.39%
Exercise price	$ 0.40
Fair value per warrant	$ 0.36
Series J Warrants March 28, 2013 [Member]
Contractual life (in months)	36 months
Expected volatility	144.30%
Risk-free interest rate	0.36%
Exercise price	$ 0.40
Fair value per warrant	$ 0.26
Series J Warrants May 20, 2013 [Member]
Contractual life (in months)	36 months
Expected volatility	147.00%
Risk-free interest rate	0.36%
Exercise price	$ 0.40
Fair value per warrant	$ 0.30
Series K Warrants December 12, 2013 [Member]
Contractual life (in months)	36 months
Expected volatility	136.10%
Risk-free interest rate	0.39%
Exercise price	$ 0.3125
Fair value per warrant	$ 0.20
Series K Warrants January 29, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	152.40%
Risk-free interest rate	0.39%
Exercise price	$ 0.3125
Fair value per warrant	$ 0.30
Series K Warrants February 28, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	152.70%
Risk-free interest rate	31.25%
Exercise price	$ 0.425
Fair value per warrant	$ 0.37
Series K Warrants June 30, 20 [Member]
Contractual life (in months)	36 months
Expected volatility	153.90%
Risk-free interest rate	31.25%
Exercise price	$ 0.375
Fair value per warrant	$ 0.29
Series K Warrants November 12, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	153.90%
Risk-free interest rate	0.90%
Exercise price	$ 0.3125
Fair value per warrant	$ 0.23
November 10, 2011 [Member]
Contractual life (in months)	60 months
Expected volatility	104.50%
Risk-free interest rate	0.875%
Exercise price	$ 0.81
Fair value per warrant	$ 0.54
Warrants Revalued at December 31, 2014 [Member]
Contractual life (in months)	22 months
Expected volatility	116.00%
Risk-free interest rate	0.58%
Exercise price	$ 0.25
Fair value per warrant	$ 0.15
Warrants Revalued at December 31, 2015 [Member]
Contractual life (in months)	11 months
Expected volatility	104.90%
Risk-free interest rate	0.65%
Exercise price	$ 0.25
Fair value per warrant	$ 0.16

Stockholders' (Deficit) - Sched

Stockholders' (Deficit) - Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Shares, Beginning balance	22,588,451	16,784,035
Shares, granted	13,401,426	10,578,500
Shares, exercised		(4,208,658)
Shares, expired	(996,678)	(534,468)
Shares, forfeited	(130,000)	(30,958)
Shares, Ending balance	34,863,199	22,588,451
Exercisable, Beginning balance	20,858,111	16,611,528
Exercisable, Ending balance	31,664,469	20,858,111
Stock Option [Member]
Shares, Beginning balance	3,406,250	1,771,708
Shares, granted	2,500,000	1,675,500
Shares, exercised
Shares, expired	(205,000)	(10,000)
Shares, forfeited	(130,000)	(30,958)
Shares, Ending balance	5,571,250	3,406,250
Weighted average price per share, Beginning balance	$ 0.51	$ 0.71
Weighted average price per share, granted	$ 0.40	$ 0.30
Weighted average price per share, exercised
Weighted average price per share, expired	$ 1	$ 1
Weighted average price per share, forfeited	0.70	0.71
Weighted average price per share, Ending balance	$ 0.44	$ 0.51
Warrants [Member]
Shares, Beginning balance	19,182,201	15,012,327
Shares, granted	10,837,141	8,903,000
Shares, exercised		(4,208,658)
Shares, expired	(791,678)	(524,468)
Shares, forfeited
Shares, Ending balance	29,227,664	19,182,201
Weighted average price per share, Beginning balance	$ 0.49	$ 0.57
Weighted average price per share, granted	$ 0.40	0.38
Weighted average price per share, exercised		0.25
Weighted average price per share, expired	$ 0.31	$ .74
Weighted average price per share, forfeited
Weighted average price per share, Ending balance	$ 0.44	$ 0.49

Stockholders' (Deficit) - Sch54

Stockholders' (Deficit) - Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Exercise Price 1 [Member]
Exercise price range, lower range limit	$ 0.30
Exercise price range, upper range limit	$ 0.39
Options outstanding, number of options | shares	1,675,500
Options outstanding, weighted average remaining contractual life	8 years 8 months 12 days
Options outstanding, weighted average exercise price	$ 0.30
Options exercisable, number of options | shares	986,612
Options exercisable, weighted average remaining contractual life	8 years 8 months 12 days
Options exercisable, weighted average exercise price	$ 0.30
Exercise Price 2 [Member]
Exercise price range, lower range limit	0.40
Exercise price range, upper range limit	$ 0.49
Options outstanding, number of options | shares	2,811,000
Options outstanding, weighted average remaining contractual life	9 years 8 months 12 days
Options outstanding, weighted average exercise price	$ 0.40
Options exercisable, number of options | shares	311,000
Options exercisable, weighted average remaining contractual life	7 years 4 months 24 days
Options exercisable, weighted average exercise price	$ 0.40
Exercise Price 3 [Member]
Exercise price range, lower range limit	0.50
Exercise price range, upper range limit	$ 0.59
Options outstanding, number of options | shares	226,250
Options outstanding, weighted average remaining contractual life	6 years 7 months 6 days
Options outstanding, weighted average exercise price	$ 0.50
Options exercisable, number of options | shares	226,250
Options exercisable, weighted average remaining contractual life	6 years 7 months 6 days
Options exercisable, weighted average exercise price	$ 0.50
Exercise Price 4 [Member]
Exercise price range, lower range limit	0.60
Exercise price range, upper range limit	$ 0.69
Options outstanding, number of options | shares	402,500
Options outstanding, weighted average remaining contractual life	4 years 1 month 6 days
Options outstanding, weighted average exercise price	$ 0.60
Options exercisable, number of options | shares	392,658
Options exercisable, weighted average remaining contractual life	4 years 1 month 6 days
Options exercisable, weighted average exercise price	$ 0.60
Exercise Price 5 [Member]
Exercise price range, lower range limit	0.70
Exercise price range, upper range limit	$ 1.25
Options outstanding, number of options | shares	456,000
Options outstanding, weighted average remaining contractual life	2 years 1 month 6 days
Options outstanding, weighted average exercise price	$ 1
Options exercisable, number of options | shares	456,000
Options exercisable, weighted average remaining contractual life	2 years 1 month 6 days
Options exercisable, weighted average exercise price	$ 1
Exercise Price 6 [Member]
Exercise price range, lower range limit	0.30
Exercise price range, upper range limit	$ 1.25
Options outstanding, number of options | shares	5,571,250
Options outstanding, weighted average remaining contractual life	8 years 3 months 18 days
Options outstanding, weighted average exercise price	$ 0.44
Options exercisable, number of options | shares	2,372,520
Options exercisable, weighted average remaining contractual life	6 years 3 months 18 days
Options exercisable, weighted average exercise price	$ 0.52

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jan. 02, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Proceeds from the sale of convertible debentures			$ 5,558,537	$ 1,126,744
Subsequent Event [Member]
Proceeds from the sale of convertible debentures	$ 1,419,667
Proceeds from short term promissory notes	$ 256,660
Subsequent Event [Member] | Investor Relations Firm [Member]
Number of restricted common stock issued		205,000